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The Regulation of PREX2 by Phosphorylation 
Douglas Barrows 
 
Phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3)-dependent RAC exchanger 
2 (PREX2) is a guanine nucleotide exchange factor (GEF) for the Ras-related C3 
botulinum toxin substrate 1 (RAC1) GTPase. As a GEF, PREX2 facilitates the exchange 
of GDP for GTP on RAC1. GTP bound RAC1 then activates its downstream effectors, 
including p21-activated kinases (PAK). PREX2, RAC1, and PAK kinases all have key 
roles within the insulin signaling pathway. The insulin receptor is a tyrosine kinase that 
phosphorylates the insulin receptor substrate (IRS) family of adaptor proteins, leading to 
the activation of phosphatidylinositide 3-kinase (PI3K) and the generation of PI(3,4,5)P3. 
PI(3,4,5)P3 then activates numerous downstream signaling proteins, including AKT and 
RAC1, to regulate several important cellular processes, such as glucose metabolism and 
cell proliferation. In addition to being a RAC1 GEF, PREX2 affects the insulin signaling 
pathway by inhibiting the lipid phosphatase activity of phosphatase and tensin homolog 
(PTEN), which dephosphorylates PI(3,4,5)P3 to antagonize PI3K. PREX2 is also 
important in cancer, which is likely a consequence of both its role as a RAC1 GEF and as 
a PTEN inhibitor. 
PREX2 GEF activity is activated by PI(3,4,5)P3 and by Gβγ, which is a 
heterodimer that is released after GPCR activation. However, PREX2 regulation within 
specific signaling pathways is poorly understood. This thesis aims to understand the 
 
   
regulation of PREX2 downstream of ligand binding to receptors on the cell surface, with 
a focus on insulin. This is achieved by studying the phosphorylation of PREX2 after 
insulin stimulation and by characterizing protein-protein interactions involving PREX2 
and key proteins in the insulin signaling pathway. 
Herein, we identified PI(3,4,5)P3-dependent phosphorylation events on PREX2 
that occur downstream of insulin stimulation. Phosphorylation of PREX2 also occurred 
downstream of Gβγ, suggesting that phosphorylation was associated with the activation 
of PREX2 GEF activity. Interestingly, phosphorylation of PREX2 reduced GEF activity 
towards RAC1 and a phospho-mimicking mutation of PREX2 at an insulin-mediated 
phosphorylation site reduced cancer cell invasion. Phosphorylation of PREX2 also 
decreased PREX2 binding to the cellular membrane, PI(3,4,5)P3, and Gβγ, providing a 
mechanism for reduced GEF activity. These data suggested that phosphorylation was part 
of a negative feedback circuit to decrease the RAC1 signal, which led to the identification 
of the PAK kinases as mediators of PREX2 phosphorylation. Importantly, insulin-
induced phosphorylation of PREX2 was delayed compared to AKT, which is consistent 
with a model where PREX2 phosphorylation by PAK occurs after activation of PREX2 
to attenuate its function. Altogether, we propose that second messengers activate the 
PREX2-RAC1 signal, which sets in motion a cascade whereby PAK kinases 
phosphorylate and negatively regulate PREX2 to decrease RAC1 activation. This type of 
regulation would allow for transient activation of the PREX2-RAC1 signal.  We then 
asked whether PAK phosphorylation of PREX2 was altered in cancer. To do this, we 
analyzed four recurrent somatic PREX2 tumor mutations, R155W, R297C, R299Q, and 
R363Q. Interestingly, all four mutants had reduced insulin and PAK1 dependent 
 
   
phosphorylation, and R297C had lower levels of phosphorylation induced by PI3K 
activating tumor mutants. This suggests that tumors might be mutating PREX2 in order to 
avoid PAK mediated negative regulation of RAC1. 
Lastly, we characterized PREX2 interactions with proteins that are critical for 
insulin signaling, with a focus on the interaction between the PREX2 pleckstrin 
homology (PH) domain and PTEN. PREX2 inhibition of PTEN is mediated by the PH 
domain, and we discovered that the β3β4 loop of the PH domain was required for binding 
of the isolated PH domain to PTEN. We also found that PREX2 co-immunoprecipitates 
with other insulin related proteins, including the p85 regulatory subunit of PI3K, IRS4, 
and the insulin receptor.   
Taken together, the studies in this thesis solidify the role of PREX2 in insulin 
signaling by showing that PREX2 GEF activity is tightly regulated by insulin and PAK-
induced phosphorylation and also by characterizing PREX2 interactions with critical 
insulin related proteins. Further, this PAK dependent negative regulatory circuit 
downstream of both PI(3,4,5)P3 and Gβγ activation of PREX2 could have impacts in 
many aspects of biology given the roles that PREX2 and RAC1 have in critical cellular 
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The binding of ligands to receptors on the cell membrane regulates intracellular 
signaling pathways, allowing cells to receive and process signals from the extracellular 
environment. Receptor activation oftentimes modulates the levels of second messengers 
within the cell. Second messengers, such as phosphatidylinositol 3,4,5-trisphosphate 
(PI(3,4,5)P3) and Gβγ, initiate signal transduction cascades that carry out fundamental 
cellular processes. Both PI(3,4,5)P3 and Gβγ stimulate the guanine nucleotide exchange 
factor (GEF) PI(3,4,5)P3-dependent RAC exchanger 2 (PREX2), resulting in the 
activation of the small GTPase Ras-related C3 botulinum toxin substrate 1 (RAC1). 
RAC1 has profound effects on both cell motility downstream of numerous ligand 
activated receptors, and glucose metabolism downstream of the insulin receptor. Herein, 
we study how PREX2 function, and therefore RAC activity, is regulated downstream of 
second messengers, with a focus on the phosphorylation of PREX2 after insulin receptor 
activation.  
 
PREX2: FUNCTION AND REGULATION WITH INSIGHTS FROM PREX1 
PREX2 discovery and structure 
PREX2 is a GEF of the small GTPase RAC1. GEFs such as PREX2 bind to RAC1 
and facilitate the exchange of guanosine diphosphate (GDP) for guanosine triphosphate 
(GTP), and while in the GTP bound state, RAC1 is able to bind many effectors and carry 
out various cellular functions. For example, GTP bound RAC1 activates the WASP-
family verprolin-homologous proteins (WAVE) regulatory complex, p21-activated kinase 
1 (PAK1), the NADPH oxidase complex, and the p110β catalytic subunit of 
phosphatidylinositide 3-kinase (PI3K) (Abo et al., 1991; Chen et al., 2010; Fritsch et al., 
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Figure 1.1 – PREX domain structure (Donald et 
al., 2004) 
2013; Manser et al., 1994). PREX2 is located on chromosome 8, q13.2, and was 
identified simultaneously by two groups based on its homology to the founding member 
of the PREX family of GEFs, PREX1. A splice variant, PREX2b, is missing a large 
portion of the C-terminal region (Donald et al., 2004; Rosenfeldt et al., 2004). PREX1 
was discovered in neutrophils during a search for a PI(3,4,5)P3 and Gβγ-stimulated RAC 
GEF regulating the formation of reactive oxygen species (Welch et al., 2002). In addition 
to RAC1, PREX1 can activate a number of other RAS (Rat sarcoma) homolog (RHO) 
family GTPases in vitro, including RAC2, RAC3, RHOG, and cell division control 
protein 42 homolog (CDC42). However, there is not yet any in vivo evidence that PREX1 
can activate CDC42 (Damoulakis et al., 2014; Welch et al., 2002). It is possible that 
PREX2 has GEF activity towards RHO GTPases other than RAC1, however this has not 
been reported. PREX2 shares 59% sequence homology with PREX1, and like PREX1, 
PREX2 is a multi-domain protein containing the tandem DH (Dbl homology) and PH 
(Pleckstrin homology) domains, two DEP (Dishevelled, Egl-10, and Pleckstrin) domains, 
two PDZ  (post synaptic density protein, disc large, and zonula occludens-1) domains, 
and a C-terminal region with homology to inositol polyphosphate-4-phosphatase (IP4P) 
(Figure 1.1) (Donald et al., 2004; Rosenfeldt et al., 2004). The DH domain is the 
functional GEF domain for 
Dbl family RHO GEFs, and 
the PH domain is often 
important in targeting the 
GEF to certain locations 
within the cell, and can 
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sometimes affect GEF activity of the DH domain (Schmidt and Hall, 2002). In addition, 
the IP4P domain of PREX1 has no reported phosphatase activity (Welch et al., 2002). 
PREX2 mRNA is widely expressed, with high expression in the skeletal muscle and 
heart, and no expression in blood leukocytes, which interestingly is where PREX1 
mRNA expression is strongest (Donald et al., 2004; Rosenfeldt et al., 2004). PREX2 
protein expression is more restricted, and is highest in the brain and lung, with weaker 
expression in the liver and adipose tissue (Donald et al., 2008; Hodakoski et al., 2014). 
Within the brain, PREX2 is most strongly expressed in the cerebellum, which is 
consistent with the reported deficiencies in Purkinje cell morphology and motor 
coordination in PREX2-/- mice (Donald et al., 2008).  
PREX2 and PREX1 GEF activity is activated by the second messengers PI(3,4,5)P3 
and Gβγ. PI(3,4,5)P3 is generated by PI3K, which can be activated downstream of 
receptor tyrosine kinase activation and also by Gβγ, which is a dimer composed of the 
beta and gamma subunits of heterotrimeric G proteins that is released upon activation of 
G-protein coupled receptors (GPCRs).  PREX2 can be directly activated by both 
PI(3,4,5)P3 and Gβγ in vitro, and expression of both PI3K and Gβγ synergistically 
activates PREX2 in vivo (Donald et al., 2004; Rosenfeldt et al., 2004). 
The involvement of PREX proteins in PI(3,4,5)P3 and Gβγ dependent RAC activation 
PI(3,4,5)P3 and Gβγ levels at the membrane are regulated by numerous ligand-
activated receptors, and PREX regulation of RAC1 has been studied in many of these 
contexts. Both PREX2 and PREX1 have roles downstream of insulin receptor activation, 
a pathway that is a focus of this thesis, and the roles of PREX proteins in insulin 
signaling will be described in more detail in a later section (Balamatsias et al., 2011; Fine 
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et al., 2009; Hodakoski et al., 2014). Expression of both PREX1 and PREX2 increase the 
level of platelet derived growth factor (PDGF) stimulated RAC activity in porcine aortic 
endothelial (PAE) cells (Donald et al., 2004; Welch et al., 2002). In addition, PDGFRβ 
knockdown in immortalized human fibroblasts blocks PREX1 driven invasive migration 
(Campbell et al., 2013). PREX2b also regulates RAC1 activity and cell migration during 
the stimulation of endothelial cells with sphingosine-1-phosphate (Li et al., 2005b). In 
PC-12 cells, knockdown of PREX1 impairs nerve growth factor mediated migration, and 
in cultured cortical neurons the expression of a dominant negative PREX1 mutant blocks 
brain derived neurotrophic factor and epidermal growth factor (EGF) driven migration 
(Yoshizawa et al., 2005). In breast cancer cells, PREX1 knockdown prevents RAC 
activation after stimulation by neuregulin, EGF, and transforming growth factor-α, all of 
which are ligands that activate epidermal growth factor receptor (EGFR) family members 
(Sosa et al., 2010). Both PREX2 and PREX1 can also bind to mammalian target of 
rapamycin (mTOR), and PREX1 knockdown reduces leucine stimulated RAC activation 
and cell migration (Hernandez-Negrete et al., 2007). Further, lipopolysaccharide (LPS) or 
tumor necrosis factor α (TNFα) primed neutrophils from PREX1-/- mice have 
significantly lower N-Formylmethionine leucyl-phenylalanine (fMLP) stimulated ROS 
formation. Given that LPS and TNFα are known to activate PI3K, this demonstrates how 
both PI(3,4,5)P3 and Gβγ inputs are important for this effect. RAC2 activation following 
fMLP treatment is also reduced in both PREX1-/- and PREX1 mutant mouse neutrophils 
(Dong et al., 2005; Welch et al., 2005). In addition, PREX1 expression increases fMLP 
dependent reactive oxygen species formation in COS cells (Nie et al., 2010). 
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Regulation of PREX1 by phosphorylation  
There are no published reports of PREX2 phosphorylation, however many groups 
have reported phosphorylation events on PREX1. Given the similarities previously 
established in the regulation of these two proteins, an understanding of PREX1 
phosphorylation may help inform how we study the regulation of PREX2. The first 
PREX1 phosphorylation event identified was shown to be mediated by cAMP-dependent 
protein kinase A (PKA). This study showed that in vitro incubation of PREX1 with 
purified PKA decreases Gβγ-induced PREX1 GEF activity. Further, when PREX1 is 
dephosphorylated with λ phosphatase, there is an increase in Gβγ-induced GEF activity 
(Mayeenuddin and Garrison, 2006). PKA phosphorylation of PREX1 blocks an 
intramolecular interaction between the IP4P and the second DEP/first PDZ domain. This 
intramolecular interaction is important for binding of PREX1 to Gβγ, Gβγ-induced GEF 
activity, and PREX1 dependent lamellipodia formation. This provides a potential 
mechanism explaining how PKA mediated phosphorylation events negatively regulate 
GEF activity (Mayeenuddin and Garrison, 2006; Urano et al., 2008).  
PREX1 is also stoichiometrically phosphorylated downstream of the ErbB receptor 
tyrosine kinase family ligand, neuregulin (NRG). Interestingly, this study showed that 
while neuregulin causes an increase in phosphorylation at both S605 and S1169, it also 
reduces phosphorylation at S315 and S319 within the PH domain. S1169 phosphorylation 
is also induced by IGF-1 in MCF-7 and T-47D breast cancer cells, by PDGF in HS578T 
breast cancer cells, and by fibroblast growth factor (FGF) in MCF7 cells. Interestingly, 
EGF is unable to stimulate S1169 phosphorylation in MCF7 cells, suggesting that this 
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phosphorylation only occurs downstream of specific growth factors (Montero et al., 
2011; Montero et al., 2013).  
Both PREX2 and PREX1 contain a highly conserved consensus PP1α binding site 
in the IP4P domain.  The PP1α consensus binding sequence has been defined as [RK]-
X(0,1)-[VI]-P-[FW], where X is any residue and P any residue but proline. PREX2 was 
identified as a PP1α binding partner in a screen for proteins that contain this consensus 
sequence, however this study did not show whether PP1α could actually dephosphorylate 
PREX2 (Hendrickx et al., 2009). A later study then showed that PP1α binds to and 
dephosphorylates PREX1, and that this dephosphorylation activates the GEF activity of 
PREX1 both in vitro and in vivo. Using mass spectrometry, they identified S1165 as a 
PP1α sensitive phosphorylation site, and showed that an alanine mutation at this residue 
mimics PP1α dephosphorylation and activates GEF activity of the protein (Barber et al., 
2012).  
Taken together, it appears that phosphorylation of PREX1 is important for its 
function, and often decreases PREX1 GEF activity. These studies present the possibility 
that PREX2 could be regulated by phosphorylation as well. 
Regulation of PREX1 membrane binding  
Localization to the cell membrane, where both PI(3,4,5)P3 and Gβγ are produced, 
is an important step in the activation of PREX1. PI3K activity and Gβγ synergistically 
increase the amount of PREX1 at the membrane, and membrane bound PREX1 has a 
higher basal GEF activity towards RAC2 (Barber et al., 2007; Zhao et al., 2007).  
Further, it appears that phosphorylation of PREX1 regulates membrane binding. Surface 
plasmon resonance experiments showed that PREX1 that has been phosphorylated in 
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vitro by PKA has reduced binding to Gβγ (Urano et al., 2008). Additionally, when human 
neutrophils are treated with the cAMP-elevating agent forskolin and the cAMP analog 6-
Bnz-cAMP, both of which activate PKA, GPCR mediated translocation of PREX1 to the 
membrane is reduced. This effect is rescued with concurrent inhibition of PKA using the 
small molecule H89 (Zhao et al., 2007).  
RAC FAMILY GTPASES  
RAC structure and regulation of activity 
Thus far, PREX2 has only been shown to have GEF activity towards RAC1, a 
member of the RHO family small GTPases. RAC1 and RAC2 were first discovered based 
on their homology to previously discovered members of the RAS and RHO families of 
GTPases. RAC1 is ubiquitously expressed, while RAC2 is primarily expressed in 
hematopoietic cells (Didsbury et al., 1989). A third family member, RAC3, is expressed 
in multiple tissues, with strong expression in the brain (Haataja et al., 1997). Lastly, 
RAC1b, a splice variant of RAC1, is most strongly expressed in the colon (Jordan et al., 
1999). 
The first known function of RAC1 and RAC2 was in the activation of an NADPH 
oxidase in response to bacterial infection in phagocytes, and this function requires GTP 
loaded RAC (Abo et al., 1991; Knaus et al., 1991). This finding was critical in that it 
demonstrates how small GTPases like RAC must be in the GTP bound state to bind many 
of its effectors. The cycling of RAC between the inactive GDP bound state and an active 
GTP bound state is tightly regulated through interactions with other proteins in the cell. 
GTPase activating proteins (GAPs) increase the GTPase activity of RAC, accelerating the 
hydrolysis of GTP to GDP, promoting the inactive, GDP bound state. In addition, 
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guanine nucleotide dissociation inhibitors (GDIs) decrease RAC activation by 
sequestering inactive RAC in the cytosol. As described previously with regards to 
PREX2 function, GEFs bind to RAC and facilitate the release of GDP once it has been 
hydrolyzed, leading to the loading of GTP (Cherfils and Zeghouf, 2013). Like other small 
GTPases, RAC structure consists of a central β-sheet made up of six strands, surrounded 
by α-helicies (six in the case of RAC1) (Hirshberg et al., 1997). Additionally, there are 
two regions of RAC1 called switch I and switch II that are critical for binding of the 
guanine nucleoside, and magnesium binding to this switch region is important for stable 
nucleoside loading. GEFs that activate RHO GTPases, including RAC, contain a catalytic 
DH domain, which binds to the switch I and II regions of RAC and alters their 
conformation to disrupt magnesium binding and allow for release of the nucleoside. 
Given that GTP is present at much higher concentrations in the cell, this results in GTP 
loading and activation of RAC (Vetter and Wittinghofer, 2001; Worthylake et al., 2000). 
Interestingly, RAC1b contains an additional 19 amino acids after the switch II region, 
and appears to be more active in cells and less sensitive to inactivation by GDIs (Matos et 
al., 2003). 
RAC1 regulation of actin polymerization 
RAC1 activation causes profound effects on the reorganization of the cytoskeleton. 
Activated RAC1 stimulates lamellipodia formation and focal adhesion complexes, 
making RAC1 a critical regulator of cell migration and cell adhesion (Nobes and Hall, 
1995; Ridley et al., 1992). Many of the RAC1 dependent functions in cell motility stem 
from the ability of RAC1 to regulate actin polymerization. Actin polymerization is 
mediated in part by the ability of GTP bound RAC to stimulate actin polymerization by 
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binding to the WAVE regulatory complex (WRC). The WRC is a multi-protein complex 
consisting of WAVE1, SRA1 (specifically RAC1-associated protein 1), NAP1 (NCK-
associated protein 1), ABI1 or 2 (ABL interactor 1 or 2) and HSPC300 (Eden et al., 
2002). While in this complex, WAVE1 is inactive and unable to nucleate actin; however, 
crystallographic studies have revealed that RAC1 relieves an inhibitory interaction 
between WAVE1 and SRA1 that occludes the WAVE VCA motif (verprolin-homology, 
central and acidic regions), which is responsible for the activation of actin 
polymerization. The binding of GTP bound RAC1 to the complex allows the WAVE1 
VCA motif to bind the ARP2/3 complex, leading to actin polymerization (Chen et al., 
2010; Eden et al., 2002; Ismail et al., 2009).  
RAC1 regulation of PAK kinases 
Another major effector of GTP bound RAC1 is the PAK family of kinases. The 
PAK family is comprised of Group I (PAK1-3) and Group II (PAK4-6) (Abo et al., 1998; 
Dan et al., 2002; Manser et al., 1994; Yang et al., 2001). All members of the PAK family 
contain a GTPase binding domain (PBD) near the N-terminus, and a conserved kinase 
domain on the C-terminus of the protein. Group I PAKs, the more extensively studied of 
the two groups, contain an auto-inhibitory domain (AID), which overlaps with the PBD. 
Group I PAKs are thought to form homodimers that keep the kinases in an inactive state. 
Upon binding to GTP bound RAC1 or CDC42, the homodimer is disrupted, allowing an 
activating autophosphorylation event in the activation loop at T423 on PAK, resulting in 
an active kinase (Lei et al., 2000). The activation of Group II PAKs is not as well 
understood. PAK4 has been the most extensively studied, and its mode of activation is 




Figure 1.2 – PAK substrates and downstream effects (Kichina et al., 2010) 
constitutively phosphorylated at S474, and its kinase activity appears to be autoinhibited 
by residues near the N-terminus of the protein that bind to the kinase domain. While it is 
known that CDC42 can bind to PAK4, it is unclear to what extent RHO GTPases can 
activate PAK4 kinase activity (Baskaran et al., 2012; Ha et al., 2012; Wang et al., 2013).   
A large number of substrates have been identified for PAK kinases resulting in a 
multitude of cellular functions (Figure 1.2). One such function is to help carry out the 
RAC1 driven cytoskeletal reorganization that occurs during lamellipodia formation. 
Phosphorylation of myosin light chain kinase (MLCK) by PAK1 reduces stress fibers in 
the cell, decreasing rigidity and promoting cell movement (Sanders et al., 1999). Both 
PAK1 and PAK4 can also phosphorylate LIM kinsase (LIMK) (Dan et al., 2001; 
Edwards et al., 1999). Once phosphorylated, LIMK phosphorylates ADF/cofilin and 
prevents the ability of ADF/cofilin to carry out its normal function in promoting 
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depolymerization of actin filaments (Arber et al., 1998). PAKs also have a role in cell 
survival by preventing apoptosis. PAK1 and PAK5 phosphorylation of RAF1 causes 
RAF1 to translocate to the mitochondria where it phosphorylates the pro-apoptotic factor, 
BCL-2 antagonist of cell death (BAD), blocking the ability of BAD to promote apoptosis 
(Jin et al., 2005; Wu et al., 2008). Furthermore, PAK1, PAK4, and PAK5 can directly 
phosphorylate and inhibit BAD (Cotteret et al., 2003; Gnesutta et al., 2001; Ye et al., 
2011). In addition, PAK activation by GTPases is important for cellular proliferation. For 
example, PAK phosphorylation of RAF1 and MEK1 is important for effective 
propagation of the RAS-MAPK-ERK signaling pathway, which regulates proliferation 
and the cell cycle (King et al., 1998; Slack-Davis et al., 2003; Sun et al., 2000; Tang et 
al., 1997; Tran and Frost, 2003).  
Activation of RAC1 in a polarized cell 
RAC1 dependent actin polymerization is critical for the chemotaxis of a cell 
towards a chemoattractant, and as previously mentioned, PREX1 and PREX2 have 
defined roles in the context of chemoattractant driven cell migration. During chemotaxis, 
a concentration gradient of chemoattractant leads to the establishment of a leading edge 
and lagging edge of a cell, with both of these poles being molecularly different. 
Chemoattractants often bind to GPCRs, which are uniformly distributed on the cellular 
membrane, and activate numerous intracellular pathways to cause cell migration, 
including the activation of PI3K to modulate PI(3,4,5)P3 levels (Servant et al., 1999; 
Xiao et al., 1997). Growth factors that bind receptor tyrosine kinases (RTKs), like PDGF, 
can also serve as chemoattractants (Grotendorst et al., 1982). Given that PREX proteins 
are activated by both RTKs and GPCRs, they are in a unique position to affect 
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chemoattractant driven RAC1 activation. One of the key consequences of receptor 
activation by chemoattractants is an increase in PI(3,4,5)P3 at the leading edge of the 
cell, allowing for activation of specific signals at the leading edge, including RAC1 
dependent actin polymerization and lamellipodia formation. In Dictyostelium, 
neutrophils, and mouse fibroblasts, it was shown that proteins with PI(3,4,5)P3 binding 
PH domains localize to the leading edge, and abrogation of PI3K activity blocks this 
effect (Funamoto et al., 2001; Haugh et al., 2000; Meili et al., 1999; Servant et al., 2000). 
Further, in Dictyostelium, gradients of the chemoattractant cAMP cause translocation of 
PI3K isoforms to the leading edge of the cell, with a concurrent localization of PTEN to 
the trailing edge, setting up a gradient of PI(3,4,5)P3 concentrations on the plasma 
membrane (Funamoto et al., 2002; Iijima and Devreotes, 2002). However, follow up 
studies have indicated that the critical role of PI(3,4,5)P3 in chemotaxis is not so 
straightforward, and is likely cell type and context dependent (Ferguson et al., 2007; 
Hoeller and Kay, 2007; Loovers et al., 2006)  
RAC1 activation by PI(3,4,5)P3 at the leading edge results in cell protrusions due to 
its roles in actin dependent lamellipodia formation and cell adhesion, two critical 
processes for cell motility (Das et al., 2000; Han et al., 1998; Shinohara et al., 2002; 
Welch et al., 2002). PREX2, in addition to a number of other RAC GEFs, contain PH 
domains that can bind membrane lipids such as PI(3,4,5)P3, and these GEFs can 
potentially regulate RAC1 at the leading edge. In contexts where PI(3,4,5)P3 is important 
for cell polarity and chemotaxis, PREX2 is likely to have an important role. 
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RAC and cancer 
 RAC has a role in many oncogenic cellular processes, such as cell migration, 
invasion, and proliferation, and there are some indications that it has a role in 
tumorigenesis. Increases in RAC1 expression have been reported in breast and colorectal 
cancers, as well as in leukemia (Fritz et al., 1999; Schnelzer et al., 2000; Wang et al., 
2009). This has been supported by publically available data on the cBio portal showing 
that RAC1 expression is elevated in many different cancer types, including breast, lung, 
stomach and uterine cancer (Cerami et al., 2012; Gao et al., 2013). Analysis of mutations 
in a cohort of melanomas showed that a P29S mutation in RAC1 occurred in 9% of sun-
exposed melanomas. This mutant displays increased binding to PAK1 and spontaneous 
loading of GTP in the absence of a GEF (Davis et al., 2013; Krauthammer et al., 2012). 
Additionally, the splice variant of RAC1, RAC1b, has increased expression in colon, 
breast, and lung tumors (Jordan et al., 1999; Schnelzer et al., 2000; Zhou et al., 2013). 
Furthermore, members of the PAK family of kinases, especially PAK1 and PAK4, are 
often overexpressed in many different types of cancer, including breast and ovarian 
cancer. In addition, PAK kinases frequently have higher levels of phosphorylation in 
cancer, suggesting they have increased levels of kinase activity (King et al., 2014)  
PREX2 and cancer  
GEFs that activate RAC1, including PREX2, are frequently altered in cancer. 
PREX2 expression is increased in many different tumor types, and PREX2 is one of the 
most frequently mutated GEFs across all cancer types, with especially high rates of 
mutation in melanoma (Cerami et al., 2012; Fine et al., 2009; Gao et al., 2013). One 
particular study sequenced 25 melanomas and found that after NRAS and BRAF, PREX2 
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was one of the most significantly mutated genes in that cohort. They also showed that 
certain PREX2 tumor mutations have functional consequences. The truncation mutants 
K278*, E824*, and Q1430*, in addition to the missense mutation G844D, cooperate with 
NRAS expression to increase tumorigenesis in a melanocyte xenograft model (Berger et 
al., 2012). Further, melanoma tumor mutants G844D and P498S, and the pancreatic 
tumor mutant V432M are able to evade inhibition of GEF activity by PTEN (Mense et 
al., 2015). Additionally, PREX2 expression is higher in breast cancers with PI3K 
activating mutations, and PREX2 cooperates with these PI3K mutations to form colonies 
in soft agar (Fine et al., 2009). PREX2 is also the target of a microRNA that is down 
regulated in metastatic neuroblastomas and gastric cancer (Chen et al., 2013; Guo et al., 
2014). PREX1 expression is also increased in cancer, including breast and prostate 
cancer, as well as melanoma (Lindsay et al., 2011; Qin et al., 2009; Sosa et al., 2010). 
 
REGULATION OF SECOND MESSENGERS THAT ACTIVATE PREX2  
  The second messengers Gβγ and PI(3,4,5)P3 both activate PREX2 GEF activity.  
They are also integral for the activation of many intracellular signals after ligand binding 
to receptors on the membrane. The regulation of Gβγ and PI(3,4,5)P3 has been 
extensively studied and will be outlined in this section. 
Gβγ  
GPCR structure and activation 
Gβγ is a dimer of β and γ subunits that is regulated by GPCRs. There are 
estimated to be over 800 different GPCRs encoded in the human genome with a wide 
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range of functions (Fredriksson et al., 2003). GPCRs have a common structure including 
seven transmembrane domains that are connected by three extracellular and three 
intracellular loops. Additionally, the intracellular C-terminus and extracellular N-
terminus of GPCRs can vary greatly in length and composition. In the absence of an 
agonist binding to a GPCR, Gα‐GDP, Gβ, and Gγ form an inactive heterotrimer. Upon 
agonist binding, the GPCR acts as a GEF to facilitate the exchange of GDP for GTP on 
Gα, and this causes dissociation of Gα‐GTP and the Gβγ heterodimer from the receptor 
(Kobilka, 2007).  
Gβγ regulation of intracellular signaling pathways 
Early studies on GPCRs made it clear that dissociation of Gα‐GTP from Gβγ 
allows Gα isoforms to regulate various intracellular signals, including the activation (Gαs)  
and inhibition (Gαi) of adenylyl cyclase to regulate cAMP levels, and the activation of 
phospholipase C (Gαq/11), which hydrolyzes PtdIns to regulate protein kinase C (PKC) 
and intracellular calcium levels. It was also originally thought that Gβγ could be a 
negative regulator of the heterotrimeric complex (Gilman, 1987). However, the discovery 
that purified Gβγ activates potassium channels in the heart showed that this signaling 
heterodimer could independently activate downstream signals upon GPCR activation 
(Logothetis et al., 1987).  This was confirmed by many studies showing that Gβγ 
activates other signaling molecules, such as adenylyl cyclase, phospholipase C-β2, 
voltage-gated calcium channels, and importantly for this thesis, PI3K (Camps et al., 
1992; Ikeda, 1996; Stephens et al., 1994; Tang and Gilman, 1991). In humans, there are 
five Gβ subunits, Gβ1-5, where Gβ1-4 share a high level of sequence homology, while Gβ5 
does not. In addition, there are 12 Gγ subunits, Gγ1‐5,  7‐13.  Gγ isoforms are not as well 
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conserved as Gβ isoforms, and much of the diversity in Gγ appears to exist on the 
outward facing residues of the protein as opposed to the region of the protein that is 
bound to Gβ. This diversity of exposed residues potentially allows for specificity for 
different Gβγ targets (Khan et al., 2013). While a role for PREX2 has not yet been 
identified downstream of any specific GPCRs or GPCR ligands, Gβγ expression can 
activate PREX2 GEF activity in insect cells. Further, PREX2b, the PREX2 splice variant, 
has a role in RAC1 activation downstream of the GPCR ligand sphingosine-1-phosphate 
(Li et al., 2005b). In addition, PREX1 has been characterized downstream of ligand 
induced GPCR activation, as highlighted above.  
PI(3,4,5)P3  
  The intracellular levels of PI(3,4,5)P3 are tightly regulated by the lipid kinase 
PI3K and the lipid phosphatase PTEN. Here, the regulation of PI3K and PTEN will be 
discussed.  
PI3K  
Prior to the identification of PI3K, it was known that kinase activity towards 
phosphoinositol (PtdIns) co-purified with gene products from cancer-inducing viruses, 
and that this lipid kinase activity was important for the transformation of cells (Kaplan et 
al., 1986; Macara et al., 1984; Sugimoto et al., 1984; Whitman et al., 1985). The inositol 
kinases responsible for this activity were later called PI3Ks based on the discovery that 
they phosphorylate PtdIns on the 3-OH position of the inositol ring, leading to the 
identification of this critical class of second messengers (Whitman et al., 1988). 
Importantly, several groups began to study signals that altered the activity of PI3Ks or the 
cellular levels of 3-OH phosphorylated lipids. Early studies identified two contexts 
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during which PI3K is activated: (1) after receptor tyrosine kinase activation in response 
to PDGF or insulin treatment and (2) after GPCR activation by fMLP (Auger et al., 1989; 
Ruderman et al., 1990; Traynor-Kaplan et al., 1989). Analysis of lipids in the cell after 
cell stimulation showed that PI(4,5)P2 was the most likely substrate for PI3Ks, and 
PI(3,4,5)P3 was established as a very important second messenger (Hawkins et al., 1992; 
Stephens et al., 1991). 
Three classes of PI3K proteins have been identified which differ in both structure 
and substrate preference. Class I PI3Ks are subdivided into two groups, Class IA and IB, 
and they function to phosphorylate PI(4,5)P2 to generate PI(3,4,5)P3. Class IA PI3Ks 
exist as a heterodimer consisting of a p85 regulatory subunit (p85α, p55α, p50α, p85β, or 
p55γ)  and a p110 catalytic subunit (p110α, p110β, or p110δ).  Class IA p110 catalytic 
subunits contain an N-terminal p85 binding domain, a RAS binding domain (RBD), a C2 
domain, a helical domain, and a lipid kinase domain, while the p85 isoforms contain a 
p110 binding domain flanked by two SH2 domains  (Escobedo et al., 1991; Hiles et al., 
1992; Hu et al., 1993; Otsu et al., 1991; Skolnik et al., 1991; Vanhaesebroeck et al., 
1997). Class IB PI3Ks have either a p87 or p101 regulatory subunit in addition to a p110γ 
catalytic subunit, which lacks the N-terminal p85-binding domain found on Class IA 
PI3Ks (Stephens et al., 1997; Stoyanov et al., 1995; Suire et al., 2005; Voigt et al., 2006). 
Class II PI3Ks contain one of three catalytic subunit isoforms, PI3K‑C2α, PI3K‑C2β, or 
PI3K‑C2γ, which phosphorylate PtdIns at the three position, with a preference for PtdIns 
and PtdIns4P. Lastly, there is only one member of Class III PI3Ks, called vacuolar 
protein-sorting defective 34 (Vps34), which can phosphorylate PtdIns to generate 
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PtdIns3P (Vanhaesebroeck et al., 2010). This thesis involves signaling events 
downstream of PI(3,4,5)P3 and therefore will focus on the Class I PI3Ks.  
PH domains have been shown to bind to phospholipids, and a small group of 
these lipid binding PH domains are able to specifically bind the PI3K products, PI(3,4)P2 
and PI(3,4,5)P3. The dynamic regulation of PI(3,4)P2 and PI(3,4,5)P3 upon PI3K 
activation allows for very specific regulation of both localization and activation of certain 
PH domain containing proteins in response to specific signals (Lemmon, 2008). For 
example, the kinase AKT, a well-studied downstream effector of PI3K signaling, 
contains a PI(3,4,5)P3 binding PH domain that is critical for its function (Manning and 
Cantley, 2007).  
AKT   
AKT was originally discovered as the homolog to a rodent viral oncogene 
(Bellacosa et al., 1991). Since then, two additional isoforms of the protein have been 
identified, AKT2 and AKT3 (Jones et al., 1991; Nakatani et al., 1999). The presence of a 
PH domain on the N-terminus of AKT suggested that lipids may regulate its kinase 
activity. It was then established that AKT kinase activity is increased in a PI3K 
dependent manner following insulin receptor activation (Cross et al., 1995; Kohn et al., 
1995). After PI3K stimulation, AKT is phosphorylated at T308 and S473, events that are 
important for activation of its kinase activity (Alessi et al., 1996). AKT is phosphorylated 
by another PI(3,4,5)P3 regulated kinase, PDK1, at T308, and also by mammalian target 
of rapamycin complex 2 (mTORC2), which is activated by RTKs, at S473 (Alessi et al., 
1997; Sarbassov et al., 2005; Stokoe et al., 1997). AKT activation leads to many 
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physiological outputs, including proliferation, cell survival, glucose uptake, and 
metabolism (Manning and Cantley, 2007). 
PI3K regulation by RTKs, Gβγ, and small GTPases 
Activation of Class I PI3Ks can be achieved through a variety of mechanisms. 
Activation can occur though the binding of SH2 domains on the p85 regulatory subunit of 
Class IA PI3Ks to phosphorylated tyrosine pYxxM motifs on growth factor receptors or 
adaptor molecules such as insulin receptor substrate (IRS) family proteins. In the basal 
state, p85 inhibits the lipid kinase activity of p110, and this inhibition is alleviated upon 
binding of p85 to these phosphorylated tyrosine residues (Auger et al., 1989; Backer et 
al., 1992; Carpenter et al., 1993; Panayotou et al., 1992). In addition to localizing p110 to 
the membrane and regulating its activation, regulatory p85 subunits also stabilize p110, 
which is critical for PI3K activity in the cell (Yu et al., 1998). Additionally, Gβγ can 
regulate Class I PI3Ks. While most of the Class IA PI3Ks are only regulated by receptor 
tyrosine kinases, PI3K that includes p110β is synergistically activated by Gβγ and 
tyrosine phosphorylated proteins (Kurosu et al., 1997). The Class IB PI3Ks are regulated 
by Gβγ; however they are not regulated by phosphorylated tyrosine residues on RTKs or 
their adaptor proteins.    This is not surprising given that the Class IB regulatory subunits 
p87 and p101 do not have SH2 domains (Stephens et al., 1997; Stoyanov et al., 1995).  
PI3Ks can also be regulated by small GTPases. RAS cooperates with tyrosine-
phosphorylated peptides to activate the p85-p110α dimer, and ablation of the RBD in 
p110α results in decreased RAS driven tumorigenesis (Gupta et al., 2007; Rodriguez-
Viciana et al., 1994; Rodriguez-Viciana et al., 1996). p110δ is also stimulated by RAS, 
however only by R-RAS and TC21 (also called R-RAS2) (Rodriguez-Viciana et al., 
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2004; Vanhaesebroeck et al., 1997). RAS can also cooperate with Gβγ to activate the 
Class IB PI3K p110γ, and neutrophils harboring a mutation that blocks the RAS-p110γ 
interaction have reduced ability to migrate towards GPCR-activating chemoattractants, a 
phenotype also seen in p110γ‐/‐  neutrophils (Pacold et al., 2000; Suire et al., 2006). 
Interestingly, p110β is not activated by RAS, but it is activated by RAC1 and CDC42, 
and this is mediated by its RBD domain (Fritsch et al., 2013).   
PTEN  
PI3K generation of PI(3,4,5)P3 is antagonized by the protein and lipid 
phosphatase PTEN.  Loss of heterozygosity on chromosome 10q23 occurs at a high rate 
in many human cancers, and three different groups identified PTEN as a candidate tumor 
suppressor that mapped to this region (Li and Sun, 1998; Li et al., 1997; Steck et al., 
1997). PTEN contains an N-terminal PIP(4,5)P2 binding domain, followed by the 
catalytic phosphatase domain, a C2 domain, and a C-terminal tail that contains a PDZ 
binding domain (Lee et al., 1999). It was established that PTEN contains the signature 
protein tyrosine phosphatase motif,  HCxxGxxR, and that PTEN weakly de-
phosphorylates serine, threonine, and tyrosine peptide substrates, with a preference for 
acidic substrates (Myers et al., 1998). In addition, PTEN reduces tyrosine 
phosphorylation of focal adhesion kinase both in vivo and in vitro (Tamura et al., 1998). 
However, the observation that PTEN is a poor protein phosphatase, and that it prefers 
very acidic substrates led to the discovery that PTEN is primarily a lipid phosphatase, 
dephosphorylating PI(3,4,5)P3 at the three position to generate PIP(4,5)P2. This is further 
supported by the fact that PTEN decreases the cellular levels of PI(3,4,5)P3 (Maehama 
and Dixon, 1998). These findings suggested that PTEN could counteract the effects of 
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PI3K and its downstream targets, such as AKT. PTEN-/- mouse embryonic fibroblasts 
(MEFs) have elevated levels of AKT phosphorylation and increased AKT kinase 
activation. Re-expression of PTEN in PTEN-/- MEFs also increases their sensitivity to 
apoptosis, and this is rescued by constitutively active AKT (Stambolic et al., 1998). 
Expression of exogenous PTEN in breast cancer cells results in both decreased 
proliferation and increased apoptosis, and the increase in apoptosis can be rescued by 
myristolated AKT, which goes to the membrane to be activated in the absence of 
PI(3,4,5)P3 (Li et al., 1998). These studies confirmed that PTEN lipid phosphatase 
activity is important in cells to counteract PI3K activation and the downstream effects of 
PI(3,4,5)P3. 
PTEN and cancer 
The role of PTEN as a tumor suppressor is well documented and is supported by 
data from human tumors and mouse models. Germline mutations in PTEN are strongly 
linked to human disease in which patients are predisposed to developing cancer, such as 
Cowden’s syndrome, where PTEN mutations occur in nearly 80% of patients (Liaw et al., 
1997; Marsh et al., 1998). Furthermore, as discussed earlier, PTEN was discovered 
because it is located in a region that is commonly deleted in cancer (Li et al., 1997; Steck 
et al., 1997). For example, loss of heterozygosity of the PTEN locus was reported in 70% 
of glioblastomas and 40% of invasive breast cancers (Singh et al., 1998; Wang et al., 
1997). PTEN is also often somatically mutated in cancer. Currently, publically available 
data shows over 1200 PTEN mutations identified in a large variety of tumor types 
(Cerami et al., 2012; Gao et al., 2013). PTEN mutations are particularly common in 
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endometrial cancer, where a recent study found that PTEN was mutated in 62% of cases 
(Cancer Genome Atlas Research et al., 2013). 
Studies in mice have also strongly supported a role for PTEN as a tumor 
suppressor. PTEN knockout mice are embryonic lethal; however, PTEN was found to be 
a haploinsufficient tumor suppressor, meaning that PTEN can contribute to tumor 
formation even in the presence of a functional PTEN allele. PTEN-/- mice develop tumors 
in many tissues, such as colon, breast, prostate, and thyroid (Di Cristofano et al., 1998; 
Podsypanina et al., 1999; Stambolic et al., 2000; Suzuki et al., 1998). Tissue specific 
knockouts of PTEN have been powerful tools to study tumor formation in the absence of 
PTEN. For example, knocking out PTEN in the breast leads to tumors within 2 months, 
and knocking out PTEN in the prostate resulted in invasive tumors within 3 weeks 
(Backman et al., 2004; Li et al., 2002; Wang et al., 2003). Further, studies in mice have 
also demonstrated that small changes in PTEN dose can alter the rate at which tumors 
form (Alimonti et al., 2010; Trotman et al., 2003).  
Regulation of PTEN phosphatase activity 
PTEN is extensively regulated by both post-translational modifications and 
protein-protein interactions. Phosphorylation of PTEN occurs primarily in the C-terminal 
tail of PTEN (C-tail). It has been shown that GSK3 can phosphorylate PTEN at S362 and 
T366 and casein kinase 2 (CK2) phosphorylates PTEN primarily at S370 and S385, in 
addition to S380, T382, and T383 (Al-Khouri et al., 2005; Miller et al., 2002; Torres and 
Pulido, 2001; Vazquez et al., 2000). It appears that phosphorylation on the C-tail of 
PTEN affects an intramolecular interaction to regulate PTEN function. Phosphorylation 
at S380, T382, T383, and S385 promotes binding of the C-tail to the catalytic region of 
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PTEN, favoring the “closed” conformation, while dephosphorylated PTEN favors an 
“open” conformation. The phosphorylated, closed form of PTEN has decreased overall 
function as it cannot efficiently bind the membrane where it dephosphorylates 
PI(3,4,5)P3 (Rahdar et al., 2009). PTEN also functions to block cell migration, and 
phosphorylation at T383 reduces the ability of PTEN to inhibit cell migration 
(Raftopoulou et al., 2004). On the other hand, the dephosphorylated, open conformation 
of PTEN can bind to the membrane more effectively and is more active, but is also less 
stable (Vazquez et al., 2000). Additionally, tyrosine phosphorylation of PTEN by SRC 
kinase decreases its phosphatase activity, while the SRC family kinase RAK increases 
PTEN stability (Lu et al., 2003; Yim et al., 2009). Multiple phosphorylation events by 
RHO-associated protein kinase (ROCK) appear to increase PTEN phosphatase activity 
(Li et al., 2005a). Lastly, studies have indicated that PTEN protein phosphatase activity 
can auto-dephosphorylate residues on its own C-tail to regulate its lipid phosphatase 
activity (Tibarewal et al., 2012; Zhang et al., 2012). In addition to phosphorylation, 
PTEN can be regulated by  other forms of post translational modification, including 
oxidation, acetylation, SUMOylation, or ubiquitylation (Hopkins et al., 2014).  
Interactions with other proteins affect PTEN function through a variety of 
different mechanisms. Some PTEN interactors, such as RAK kinase and melanocortin-1 
receptor (MC1R), have been shown to increase PTEN stability by disrupting PTEN 
ubiquitylation and proteosomal degradation (Cao et al., 2013; Yim et al., 2009). PTEN 
membrane localization is also regulated by protein interactions. MAGI proteins, β-
arrestins, Na+/H+ exchanger regulatory factor (NHERF), neutral endopeptidase (NEP), 
and the PI3K regulatory subunit p85 all promote PTEN membrane localization where it 
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can be part of important signaling complexes (Chagpar et al., 2010; Kotelevets et al., 
2005; Lima-Fernandes et al., 2011; Sumitomo et al., 2004; Takahashi et al., 2006; 
Tolkacheva et al., 2001; Wu et al., 2000a; Wu et al., 2000b). In contrast, cytosolic α-
mannosidase 2C1 (MAN2C1) inhibits PTEN phosphatase activity, and it was speculated 
it might prevent PTEN membrane binding (He et al., 2011).  
PREX2 inhibition of PTEN phosphatase activity  
Previous work from our lab has shown that PTEN also interacts with PREX2, 
resulting in inhibition of PTEN phosphatase activity. In vitro, PREX2 inhibits PTEN 
phosphatase activity in a non-competitive manner with the substrate PI(3,4,5)P3. In 
PTEN deficient U87MG glioblastoma cells, PTEN expression causes an expected 
decrease in AKT phosphorylation, and PREX2 expression rescues this effect, suggesting 
that this inhibition occurs in cells. PREX2 knockdown by shRNA decreases the rate of 
proliferation in MCF7 breast cancer cells, which contain PTEN, however this effect is not 
seen in BT549 cells, a PTEN-null breast cancer cell line (Fine et al., 2009). Taken 
together, these data suggest that PREX2 can bind to PTEN and inhibit its ability to 
dephosphorylate PI(3,4,5)P3 and antagonize PI3K signaling in cells.  
Mechanism of PTEN inhibition by PREX2  
Further work to characterize the mechanism of PREX2 mediated inhibition of 
PTEN showed that phosphorylation on the C- tail of PTEN at S380, T382, and T383 is 
required for inhibition of PTEN phosphatase activity. When either wild type PTEN or 
PTEN S380A/T382A/T383A was expressed and immunoprecipitated from PTEN null 
U87MG cells, only in the context of wild type PTEN did PREX2 expression reduce 




Figure 1.3 – Model of PH domain mediated inhibition of PTEN phosphatase 
activity by PREX2 The PREX2 DH domain blocks PH domain mediated inhibition 
of PTEN when PTEN is not phosphorylated. The DH domain senses PTEN 
phosphorylation, revealing the region of the PREX2 PH domain that can inhibit 
PTEN (Hodakoski et al., 2014). 
for inhibition. Full length PREX2 or PREX2 DHPH domain does not inhibit bacterial 
GST PTEN, while purified PREX2 PH domain can. Given that bacterial GST PTEN is 
not phosphorylated, this suggests that phosphorylation of PTEN is not required for 
inhibition by the PH domain. In addition, the mechanism of binding between PREX2 and 
PTEN was analyzed. In pull-down experiments using GST PTEN, in vitro translated 
PREX2 PH domain binds to the phosphatase and C2 domains of PTEN; however, in cells 
this interaction is relatively weak. Further, the C-terminal IP4P domain of PREX2 binds 
strongly to the PDZ binding domain at the C-terminus of PTEN. The proposed model is 
that this high affinity interaction involving the PDZ binding domain of PTEN and the 
IP4P domain of PREX2 initiates binding between the two proteins (Figure 1.3). This then 
puts the DHPH domain of PREX2 in close proximity to the phosphatase and C2 domains 
of PTEN, resulting in the inhibition of PTEN. Further, when PTEN is not 
phosphorylated, the DH domain of PREX2 potentially binds to the PH domain and 
prevents it from inhibiting PTEN. When PTEN is phosphorylated, the DH domain can 
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sense the phosphorylation state of PTEN, which changes the conformation of PREX2 so 
that the PH domain is revealed and can inhibit PTEN phosphatase activity (Hodakoski et 
al., 2014). This is the first report of PH domain mediated inhibition of PTEN. Given the 
high number of mammalian proteins that contain PH domains, PH domain mediated 
inhibition of PTEN could represent a common mechanism of regulation, an exciting 
possibility given the importance of PTEN in many physiological processes.  
PTEN inhibition of PREX2 GEF activity  
Studies from our lab showed that the interaction between PREX2 and PTEN also 
results in inhibition of PREX2 GEF activity (Mense et al., 2015). This provides a 
potential mechanism for the previously characterized role of PTEN in reducing cell 
migration (Raftopoulou et al., 2004; Tamura et al., 1998). PTEN inhibits PREX2 GEF 
activity in vitro and also blocks PREX2 driven cell invasion and migration, and these 
effects do not require the phosphatase activity of PTEN. Further, PTEN-/- MEFs show 
increased invasion, and this effect is ablated in PTEN-/- PREX2-/- MEFs, suggesting that 





In this thesis, we focus on PI(3,4,5)P3-mediated regulation of PREX2 in the 
insulin signaling pathway. As will be discussed below, PREX2 has an important role in 
insulin signaling and insulin-mediated glucose metabolism, which is likely a result of 
both RAC1 activation and PTEN inhibition.  
Overview of insulin signaling 
Insulin is a hormone that is produced in the β-cells of the pancreas in response to 
the high levels of carbohydrates and amino acids in the blood. Insulin then acts on 
multiple organs within the body, and a primary function of insulin is to reduce blood 
glucose levels. The molecular mechanisms by which insulin achieves this effect will be 
discussed in this section.  
Insulin was first purified from pancreatic extracts to treat diabetic patients by 
Frederick Banting and Charles Best in 1922 (Banting et al., 1922). In 1950 it was shown 
that insulin regulates blood glucose levels by increasing the permeability of cellular 
membranes for glucose, and it was later discovered that insulin exerts its effects by 
binding to the insulin receptor on the cell membrane (Freychet et al., 1971; Levine et al., 
1950). Characterization of the insulin receptor revealed that it is a tyrosine kinase 
consisting of two extracellular α subunits and two cytoplasmic β subunits (Ebina et al., 
1985; Ullrich et al., 1985). Binding of insulin to the α subunits results in 
autophosphorylation of the β subunits, which activates the tyrosine kinase activity of the 
receptor (Avruch et al., 1982; Kasuga et al., 1982a; Kasuga et al., 1982b; Petruzzelli et 
al., 1982; Van Obberghen and Kowalski, 1982). A key group of proteins that are 
phosphorylated by the insulin receptor belong to the IRS family (White et al., 1985). 
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Figure 1.4 – Intracellular insulin signaling and physiological effects (Taniguchi et 
al., 2006) 
Once phosphorylated, IRS proteins can then bind the p85 regulatory subunit of PI3K to 
activate PI3K and increase PI(3,4,5)P3 at the membrane, activating important 
downstream effectors, including AKT and RAC1, to carry out insulin dependent 
physiological outputs (Figure 1.4) (Backer et al., 1992; Ruderman et al., 1990).  
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Role of AKT in glucose metabolism 
AKT has a critical role in regulating glucose levels in the blood in response to 
insulin stimulation. In cultured 3T3-L1 adipocytes, siRNA knockdown of AKT1 or 
AKT2 reduces glucose uptake, with AKT2 having a stronger effect. Further, knockdown 
of both AKT1 and AKT2 together significantly reduces GLUT4 levels at the membrane 
(Jiang et al., 2003). On the other hand, overexpression of a constitutively active form of 
AKT in 3T3-L1 adipocytes increases glucose uptake and GLUT4 at the membrane (Kohn 
et al., 1996). AKT2-/- mice are diabetic as they have higher blood glucose levels during 
resting state and during a glucose tolerance test. Also, glucose uptake is significantly 
reduced in isolated muscle from AKT2-/- mice when compared to wild type counterparts 
(Cho et al., 2001a).  
A number of AKT substrates that are important for glucose regulation have been 
identified. AKT increases glucose storage through phosphorylation of GSK3, a kinase 
that phosphorylates and inhibits glycogen synthase. Phosphorylation by AKT inhibits 
GSK3 kinase activity, leading to an increase in the synthesis of the glucose storage 
polymer glycogen (Cross et al., 1995). AKT also decreases glucose production in the 
liver through phosphorylation of forkhead box O (FOXO) proteins. Phosphorylation of 
FOXO by AKT prevents their translocation to the nucleus where they carry out their 
function as transcription factors (Brownawell et al., 2001; Brunet et al., 1999). FOXO 
transcription factors increase the expression of genes that promote gluconeogenesis in the 
liver, and exclusion from the nucleus after AKT phosphorylation results in a reduction in 
liver glucose production (Gross et al., 2008). AKT also phosphorylates a number of 
substrates to increase insulin regulated glucose uptake in muscle and adipose tissue, 
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specifically affecting the transport of the main glucose transporter, GLUT4, to the 
membrane. In a basal state, GLUT4 is often sequestered in various intracellular 
membrane structures, and upon insulin binding, rates of both endocytosis and exocytosis 
are regulated to increase levels of GLUT4 at the membrane. Insulin activation of AKT 
leads to phosphorylation and inhibition of a RAB GAP called AKT substrate of 160 kDa 
(AS160), which results in increased GLUT4 translocation to the membrane (Kane et al., 
2002; Sano et al., 2003). AKT2 also phosphorylates RGC2, which is a GAP for the 
GTPase RALA. RALA is a component of GLUT4 storage vesicles (GSVs), and active 
GTP-bound RALA is critical for the recognition of GSVs by the exocyst complex on the 
membrane. Insulin-stimulated phosphorylation of RGC2 by AKT2 blocks the RGC2 
inhibition of RALA activity, promoting targeting of GSVs to exocysts (Chen et al., 2007; 
Chen et al., 2011). Lastly, AKT2 phosphorylates the 138kDa C2-domain containing 
phosphoprotein (CDP138), shown to affect the fusion step of GSVs with the membrane 
resulting in GLUT4 receptors being available for insulin binding (Xie et al., 2011).  
The role of RAC GTPases and PAK kinases in glucose uptake  
 RAC1 has also been identified as an important mediator for glucose uptake in 
skeletal muscle cells, and this effect depends on PI3K generation of PI(3,4,5)P3. It is 
thought that RAC1 does not play a significant role in glucose uptake in adipocytes, where 
another protein, TC10, regulates glucose uptake in a PI3K independent manner (JeBailey 
et al., 2004). However, a study in mouse 3T3-L1 adipocytes showed that PREX1 is 
important for glucose uptake, and that this occurs through RAC1, suggesting a potential 
role for RAC1 in adipocytes (Balamatsias et al., 2011). In rat muscle cells, RAC1 is 
quickly activated following insulin stimulation, and blocking RAC1 function, either by 
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siRNA or expression of a dominant negative form of the protein, reduces GLUT4 
translocation to the cell membrane, while constitutively active RAC1 has the opposite 
effect (Chiu et al., 2013; JeBailey et al., 2007; Khayat et al., 2000; Ueda et al., 2008). 
Further, in muscle specific RAC1 knockout mice, there is deficient glucose uptake in the 
muscle and higher levels of glucose in the blood during glucose tolerance test (Sylow et 
al., 2013; Ueda et al., 2010).  
The major RAC1 output that is critical for glucose uptake is the stimulation of 
actin polymerization, which is necessary for GSVs to bring GLUT4 to the membrane. 
Insulin treatment causes actin remodeling, and when the actin network is disrupted by 
pharmacologic agents, such as cytochalasin D, GLUT4 is no longer able to translocate to 
the membrane (Tong et al., 2001; Tsakiridis et al., 1994; Wang et al., 1998). In rat muscle 
cells, both the expression of dominant negative RAC1 and the knockdown of RAC1 
using siRNA block insulin-induced actin remodeling (JeBailey et al., 2007; Khayat et al., 
2000). In addition, the established effector of RAC1 activation that is required for actin 
polymerization, ARP2/3, is necessary for GLUT4 translocation to the membrane after 
insulin binding (Chiu et al., 2010). These studies show that actin rearrangement 
downstream of RAC1 activation is important for glucose uptake.  
 In addition, the RAC1-GTP activated kinase PAK1 is an important mediator of 
glucose uptake downstream of RAC1 activation. PAK1 is activated after insulin 
stimulation, an effect that requires PI3K activity (Tsakiridis et al., 1996).  Further studies 
in mice revealed that GLUT4 membrane translocation following insulin stimulation in 
skeletal muscle of PAK1-/- mice is defective compared to wild type littermates (Wang et 
al., 2011). Insulin dependent GLUT4 translocation, glucose uptake, and actin remodeling 
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is also reduced in L6 rat myoblasts after pharmacological inhibition of PAK1 (Tunduguru 
et al., 2014). In addition, the actin-regulating protein cofilin, which is downstream of the 
PAK1 substrate LIMK, is required for the actin changes necessary for GLUT4 
translocation (Chiu et al., 2010).  
Role of PREX2 in insulin signaling and glucose metabolism 
Given the dual roles of PREX2 as a RAC1 GEF and a PTEN inhibitor, and the 
importance of RAC and PI3K signaling for propagation of the insulin signal, our lab 
hypothesized that PREX2 would be important for insulin signaling, which was confirmed 
in the analysis of PREX2-/- mice. Following insulin treatment, there is a reduction in the 
stimulation of phosphorylation of AKT and the phosphorylation of its downstream targets 
GSK3β and FOXO1/3 in both the adipose and liver tissue of the PREX2-/- mice. In livers 
of wild type mice, PTEN phosphatase activity is reduced following insulin treatment, and 
this effect is not observed in the PREX2-/- mice, suggesting that PREX2 is altering PTEN 
function in the mouse. Additionally, PREX2-/- MEFs show reduced insulin and IGF1 
stimulated phosphorylation of AKT, GSK3β, and FOXO1/3 up to at least 60 minutes 
after stimulation. Interestingly, signaling downstream of EGF and PDGF stimulation is 
unaffected in the PREX2-/- MEFs, suggesting that the role of PREX2 in growth factor 
signaling may be specific for insulin and IGF1. This possibility is strengthened by the 
fact that PREX2 interacts with the phosphorylated insulin receptor, but not with the 
phosphorylated EGF receptor (Hodakoski et al., 2014).  
PREX2 loss in mice also leads to increased glucose in the blood after glucose or 
insulin injection (Hodakoski et al., 2014). These data show a clear role of PREX2 in 
insulin mediated glucose uptake, however the mechanism for this effect is less certain. 
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Both AKT and RAC1 are especially important for glucose metabolism, and given the 
dual roles of PREX2 as an inhibitor of PTEN and an activator of RAC1, it is likely that 
both functions are involved in PREX2 mediated glucose uptake. To date, there is no data 
describing a mechanism for PREX2 regulation downstream of insulin receptor activation. 
It is unclear whether there are additional modes of regulation for PREX2 other than 
simply increasing levels of PI(3,4,5)P3 at the membrane, leading to activation of PREX2. 
It is likely that PREX2 function downstream of insulin is modified by other signaling 
molecules through protein-protein interactions or post-translational modifications, a 
possibility thoroughly investigated in this thesis.  
Mechanisms of insulin resistance 
 Defective insulin signaling in multiple tissues results in insulin resistance, which 
is an underlying cause of the widespread disease Type 2 diabetes. Disruption of the 
insulin signaling pathway at many levels has been shown to contribute to insulin 
resistance. IRS proteins appear to be particularly important. IRS1 mutations identified in 
a cohort of highly insulin resistant patients leads to reduced insulin signaling, and both 
IRS1 and IRS2 knockout mice are insulin resistant (Araki et al., 1994; Tamemoto et al., 
1994; Whitehead et al., 1998; Withers et al., 1998). Further, AKT2 knockout mice are 
insulin resistant, and this appears to be specific for this isoform given that this phenotype 
is not seen in mice lacking AKT1 (Cho et al., 2001a; Cho et al., 2001b). AKT activity is 
also reduced in skeletal muscle tissue from patients with diabetes, and a family with 
inherited diabetes carried a mutation in AKT2 that disrupts kinase activity in vitro and 
reduces insulin signaling in cells (George et al., 2004; Krook et al., 1998). FOXO 
transcription factors, which produce glucose in the liver, have also been linked to insulin 
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resistance in mice. Mice expressing constitutively active FOXO1 that cannot be inhibited 
by AKT develop insulin resistance, while the loss of one FOXO1 allele restores insulin 
sensitivity in mice that are heterozygotic for the insulin receptor (Nakae et al., 2002). 
Further, PTEN activity is associated with changes in insulin sensitivity in humans and in 
mice, which is not surprising given the importance of PTEN in regulating PI(3,4,5)P3. 
Patients with PTEN mutations are reported to have lower measures of insulin resistance 
(Pal et al., 2012). In mice, PTEN heterozygosity restores β-cell function and insulin 
sensitivity that is reduced in IRS2-/- mice (Kushner et al., 2005). Adipose specific PTEN-/- 
mice show increased insulin sensitivity, and muscle specific knockout of PTEN protects 
mice from insulin resistance after being fed a high fat diet (Komazawa et al., 2004; 
Wijesekara et al., 2005). In addition, activation of RAC1, a critical mediator of glucose 
uptake in the insulin pathway, can have reduced expression in diabetic patients (Sylow et 
al., 2013; Sylow et al., 2014).  
Much of the recent research on diabetes and insulin resistance has focused on 
trying to determine the actual cause of reductions in insulin signaling that can lead to 
disease. Given that the single biggest risk factor for diabetes is obesity, the link between 
lipids and insulin resistance has been explored. Infusion of free fatty acids into healthy 
human subjects can reduce glucose metabolism and insulin signaling in muscle (Dresner 
et al., 1999; Roden et al., 1996). Metabolism of high levels of intracellular lipids results 
in increased amounts of lipid intermediates, and some of these intermediates may cause 
insulin resistance. For example, increases in diacylglycerol (DAG) levels following free 
fatty acid infusion have been strongly linked to insulin resistance. Increases in 
intracellular DAG are associated with a concurrent increase in PKCθ  kinase activity, 
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leading to IRS1 serine phosphorylation and a decrease in insulin signaling and glucose 
uptake in muscle (Yu et al., 2002). Furthermore, fatty acids can bind and activate GPCRs, 
such as GPR41 and GPR120, to increase glucose uptake in mouse adipose and muscle 
cells (Han et al., 2014; Oh et al., 2010). It is possible that perturbations in these fatty 
acid-stimulated pathways, or desensitization or downregulation of these receptors caused 
by high plasma fatty acid levels, could also be contributing to insulin resistance. In 
addition, contexts of cellular stress such as the unfolded protein response and 
inflammation are also associated with insulin resistance (Samuel and Shulman, 2012). 
Given that PREX2 has an established role in insulin signaling and glucose uptake, it is 
possible that PREX2 is important in the development in insulin resistance. This is 
supported by the finding that PREX2 protein expression is lower in adipose tissue from 
insulin resistant human subjects (Hodakoski et al., 2014).  
 
THE NEED FOR A BETTER UNDERSTANDING OF PREX2 REGULATION  
 The two known roles of PREX2 in cellular signaling, as a PI(3,4,5)P3 and Gβγ 
dependent RAC GEF and an inhibitor of PTEN phosphatase activity, give PREX2 the 
potential to impact many physiological processes. However, very little is known about 
the mechanism of PREX2 regulation downstream of ligand activation of membrane 
receptors. Given the complex regulation of other RHO GEFs by post-translational 
modifications or through interactions with other proteins, we hypothesized that PREX2 is 
also regulated by similar mechanisms (Rossman et al., 2005). Further, a more complete 
understanding of PREX2 regulation will potentially lead to novel ways to target and 
modulate RAC1 activity or PTEN phosphatase activity in the widespread diseases in 
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which they play a role, such as cancer and diabetes. Here, we characterize the regulation 
of PREX2 by phosphorylation and protein-protein interactions, with a focus on the 



























BACKGROUND AND SIGNIFICANCE  
PREX2 can be directly activated by both PI(3,4,5)P3 and Gβγ in vitro, and 
expression of both PI3K and Gβγ synergistically activates PREX2 in vivo (Donald et al., 
2004; Rosenfeldt et al., 2004). PI(3,4,5)P3 is generated by PI3K following receptor 
tyrosine kinase and GPCR activation and Gβγ is released after GPCR activation. The 
levels of these second messengers are regulated by numerous ligand-activated receptors 
and PREX proteins have been studied in many of these contexts. One particular context 
where PREX2 plays an important role is in the insulin-signaling pathway. The insulin 
receptor is a receptor tyrosine kinase that stimulates PI3K, activating RAC1 and AKT, 
both of which are critical for regulating glucose metabolism in many tissues (Alessi et al., 
1996; JeBailey et al., 2004; Khayat et al., 2000; Ruderman et al., 1990; Taniguchi et al., 
2006). In mice, PREX2 loss leads to increased glucose in the blood after glucose or 
insulin injection. Further, in liver and adipose tissue, PREX2 knockout reduces the 
phosphorylation of AKT and its substrates after insulin stimulation (Hodakoski et al., 
2014). These phenotypes are likely the result of both PREX2 GEF activity towards RAC1 
and PREX2 inhibition of PTEN (Fine et al., 2009).  
Despite the known roles of PREX2 in insulin signaling, very little is known about 
PREX2 regulation downstream of insulin receptor activation. Though there are no reports 
of PREX2 phosphorylation, we hypothesized that phosphorylation is likely to be 
important for PREX2 regulation and function, especially given that phosphorylation can 
regulate the function of PREX1 and other RAC GEFS, such as VAV and T-lymphoma 
invasion and metastasis-inducing protein 1 (Tiam1) (Aghazadeh et al., 2000; Fleming et 




Figure 2.1 - PREX2 undergoes a Lambda phosphatase 
sensitive electrophoretic mobility shift in response to 
insulin A) Western blot analysis of V5 PREX2 that was 
isolated from starved or insulin treated (5μg/mL for 30 
minutes) HEK293 cells and then treated with Lambda 
phosphatase.  B) Western blot analysis of endogenous 
PREX2 that was immunoprecipitated from starved or insulin 















2006; Montero et al., 2011; Montero et al., 2013; Urano et al., 2008). In this chapter, we 
explore the possibility of PREX2 regulation by phosphorylation downstream of insulin 
receptor activation.  
RESULTS 
PREX2 is phosphorylated downstream of insulin receptor activation by a PI3K 
dependent mechanism 
  Given the established role of PREX2 in insulin signaling, we tested the 




PREX2. When V5 
PREX2 was 
expressed in 
HEK293 cells that 
were treated with 
insulin, enrichment 
of a slower 
migrating species of 
PREX2 was 
detected relative to starved cells after gel electrophoresis. Treatment of V5 PREX2 with 
Lambda phosphatase, a non-specific protein phosphatase, eliminated the insulin-induced 





Figure 2.2 - PREX2 phosphorylation is induced by insulin and IGF1, but not 
EGF Western blot analysis of HEK293 cells expressing V5 PREX2, which were 
starved and treated with insulin, 50ng/mL IGF, or 50ng/mL EGF for the indicated 
times. 







2.1A). When endogenous PREX2 was immunoprecipitated from insulin-treated HEK293 
cells, a Lambda phosphatase sensitive electrophoretic mobility shift was also observed 
(Figure 2.1B).  It is important to note that the endogenous PREX2 is almost completely 
shifted, suggesting that under physiologic conditions PREX2 is stoichiometrically 
phosphorylated by a signal activated by insulin.  
 To determine whether phosphorylation of PREX2 is specific to the insulin-
signaling pathway, we analyzed the electrophoretic mobility shift downstream of IGF1 
and EGF. IGF1 induced the phosphorylation of PREX2; however, treatment with EGF 
had no effect (Figure 2.2). While ERK signaling was stimulated by EGF in these cells, 
AKT signaling was induced only slightly, indicating that PI3K was probably not 
significantly activated under these conditions. This result suggested that phosphorylation 
of PREX2 could be PI3K dependent. We tested this hypothesis with the pan class I PI3K 
inhibitor GDC0941, and found that this drug eliminated insulin-induced phosphorylation 





Figure 2.3 - PREX2 phosphorylation is PI3K dependent A) Western blot 
analysis of V5 PREX2 expressing HEK293 cells, which were starved and 
treated with DMSO or 500nM GDC0941, 500nM MK2206, 5μM 
GSK2334470, or 20nM Rad001 followed by treatment with insulin. B) 
Western blot analysis of starved U87MG cells expressing V5 PREX2, and 

















































could phosphorylate PREX2. Using small molecule inhibitors, we tested whether AKT, 
PDK1, or mTORC1, three kinases activated by PI(3,4,5)P3 downstream of insulin 
receptor activation, had a role in the phosphorylation of PREX2. These inhibitors had no 
effect on PREX2 phosphorylation, suggesting that PREX2 is either phosphorylated by 
PI3K directly, or by another kinase downstream of PI(3,4,5)P3. In PTEN-null U87MG 
glioblastoma cells, expression of two tumor hotspot mutants that constitutively activate 
the catalytic PI3K subunit p110α, E545K and H1047R, induced PREX2 phosphorylation, 
confirming that phosphorylation of PREX2 is mediated by PI3K (Figure 2.3B). These 
data show that PREX2 is phosphorylated after insulin stimulation through a PI3K 





Figure 2.4 - PREX2 is a phosphorylated protein Mass spectrometry analysis was 
performed on V5 PREX2 isolated from HEK293 cells that were unstimulated (starved and 
treated with 500nM GDC0941) or stimulated (insulin alone or combined with 100nM 
calyculin A). A) Coomassie blue stain of purified PREX2. B) Identified phosphorylated 
residues on PREX2 from all conditions. Residues in blue are those only identified in one 
of the stimulated conditions.  
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PREX2 is heavily phosphorylated, including at the insulin sensitive site, S1107 
To identify PREX2 phosphorylation sites, we analyzed immunoprecipitated V5 
PREX2 from HEK293 cells by mass spectrometry. PREX2 was purified from starved 
HEK293 cells that were treated with ether the PI3K inhibitor GDC0941, insulin alone, or 
insulin in combination with the PP1/PP2A inhibitor, calyculin A (Figure 2.4A). Mass 
spectrometry analysis revealed a total of 19 serine and threonine phosphorylation sites, 
12 of which were only identified on PREX2 from stimulated cells (cells treated with 
insulin alone or in combination with calyculin A) (Figure 2.4B). Using the Scansite 
online tool under medium stringency we found that none of our phosphorylated residues 
fit a consensus motif of a kinase that is known to be activated by insulin and is included 




Figure 2.5 – S1107 is an insulin and PI3K dependent phosphorylation site A) 
Western blot analysis of HEK293 cells expressing either V5 PREX2 WT or 
S1107A that were starved or treated with insulin. B) Western blot analysis of 
HEK293 cells expressing either V5 PREX2 WT or S1107A. C) Western blot 
analysis of HEK293 cells expressing V5 PREX2 that were starved and then 
treated with DMSO or 500nM GDC0941 followed by treatment with insulin. D) 
Western blot analysis of DBTRG cells that were transiently transfected with 
control or PREX2 siRNA, and then starved and treated with DMSO or 500nM 
GDC0941 followed by insulin treatment. 
2003).  
To determine which of these phosphorylation events are regulated by insulin, we 
made alanine mutants at sites that were phosphorylated in the stimulated condition and 
determined the effect on the electrophoretic mobility of PREX2. We found that an 
alanine mutation at S1107 reduced enrichment of the slower migrating, phosphorylated 
form of PREX2 after insulin stimulation (Figure 2.5A). After developing an antibody to 
S1107, we confirmed that the antibody could not recognize PREX2 S1107A, 
demonstrating that the antibody is specific for the phosphorylated form of PREX2 at 
S1107 (Figure 2.5B). Importantly, phosphorylation of S1107 on V5 PREX2 was 
increased after insulin treatment and enriched in the slower migrating form of PREX2 
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(Figure 2.5C). S1107 phosphorylation was also eliminated by PI3K inhibition. These data 
show that S1107 is an insulin regulated phosphorylation site; however, it is important to 
note that the alanine mutation at this residue did not completely eliminate the upper band 
of PREX2, suggesting that other insulin sensitive phosphorylation sites exist. To confirm 
that endogenous PREX2 is phosphorylated at S1107, DBTRG glioblastoma cells, which 
contain high levels of endogenous PREX2, were treated with insulin and GDC0941 
(Figure 2.5D) (Fine et al., 2009). As expected, phosphorylation at S1107 increased after 
insulin treatment and was reduced upon PI3K inhibition. DBTRG cells with PREX2 
transiently knocked down by siRNA were used as controls to verify that the S1107 signal 
was specific to PREX2. Taken together, we identified S1107 as an insulin and PI3K 
dependent phosphorylation site, the first signal dependent phosphorylation event reported 
for PREX2.  
Phosphorylation of PREX2 is regulated by the protein phosphatases PP1α and PP2A  
 As shown in Figure 2.4, the mass spectrometry analysis revealed only serine and 
threonine phosphorylation sites on PREX2, many of which were detected with a PP1 
inhibitor. It has also been reported that PP1α binds a fragment of PREX2 that contains a 
consensus PP1α binding site (Barber et al., 2012; Hendrickx et al., 2009). These data led 
us to test the hypothesis that PP1α could dephosphorylate PREX2. First, we confirmed 
that PREX2 could bind to GST PP1α (Figure 2.6A). Additionally, the PREX2-PP1α 
interaction was eliminated by mutating two critical residues within the PP1α consensus 
binding site, V1085 and F1087, to alanine. Treatment of WT PREX2 with calyculin A 
stimulated phosphorylation of PREX2 even in the absence of insulin, and resulted in a 





Figure 2.6 – PP1α can dephosphorylate PREX2 A) Western blot analysis of GST 
or GST PP1α pull downs from HEK293 cells expressing either V5 PREX2 WT or 
1085/87A. B) Western blot analysis of HEK293 cells expressing V5 PREX2 WT or 
1085/87A with or without co-expression of V5 PP1α. Cells were starved and then 
treated with DMSO or 100nM calyculin A, followed by treatment with insulin. C) 
The ability of GST PP1α to dephosphorylate V5 PREX2 isolated from HEK293 
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PP1α eliminated the insulin-induced phosphorylation of PREX2; however, the 1085/87A 
mutant, which cannot bind PP1α, was insensitive to PP1α dephosphorylation. To test 
whether PREX2 is a direct substrate of PP1α, we performed an in vitro phosphatase 
assay, and found that GST PP1α efficiently dephosphorylated PREX2 (Figure 2.6C). 
Further, S1107 phosphorylation was ablated by PP1α overexpression and by GST PP1α 
in vitro, showing that this is a PP1α sensitive phosphorylation event (Figure 2.6B, C). 
 Since the 1085/1087A mutant does not bind PP1α, it was surprising that it was not 
always in the maximally shifted form that is seen after calyculin A treatment (Figure 
2.6B). We hypothesized that PP2A, which is also inhibited by calyculin A, is able to 
compensate for the absence of PP1α regulation by dephosphorylating PREX2. To probe 




Figure 2.7 – PP2A can dephosphorylate PREX2 A) Western blot analysis of 
starved V5 PREX2 WT or 1085/87A expressing HEK293 cells that were 
treated with the indicated concentrations of okadaic acid for 30 minutes. B) 
The ability of purified PP2A to dephosphorylate V5 PREX2 isolated from 
HEK293 cells was assessed and analyzed by Western blot. C) Western blot 
analysis of HEK293 cells expressing V5 PREX2 with or without co-
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towards PP2A at low doses (Cohen et al., 1989). When treated with okadaic acid, 
phosphorylation of PREX2 was increased, suggesting that PP2A may have a role in 
PREX2 dephosphorylation (Figure 2.7A). The 1085/1087A mutant was phosphorylated 
more than wild type PREX2 at all doses, indicating that PP1α contributes to PREX2 
dephosphorylation when PP2A is inhibited. We then performed an in vitro PP2A 
phosphatase assay to show that PP2A dephosphorylates PREX2 (Figure 2.7B). Lastly, 
overexpression of the PP2A catalytic subunit reduced phosphorylation of PREX2, 
including at S1107, although not nearly as efficiently as PP1α (Figure 2.7C). From this 
data, it is clear that phosphatases are important in regulating PREX2 phosphorylation, 




Figure 2.8 – PREX2 is not a PI3K substrate A) Western blot analysis of U87MG 
cells expressing V5 PREX2 and either PTEN WT or the lipid phosphatase dead 
mutant PTEN G129E. B) (Left) In vitro kinase assay with purified PI3K and V5 
PREX2 isolated on V5 agarose beads, performed with or without GDC0941. 
Incorporation of [γ-32P]-ATP was analyzed by gel electrophoresis. (Right) In vitro 
kinase assay with purified PI3K and phosphatidylinositol, performed with or without 
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PREX2 phosphorylation is dependent on binding to PI(3,4,5)P3 
We next sought to understand how PREX2 phosphorylation was regulated after 
insulin stimulation to better inform our search for a PREX2 kinase. Our data from 
Figures 2.2 and 2.3 suggest that PREX2 is either phosphorylated by PI3K, or by a kinase 
downstream of PI(3,4,5)P3 generation. We found that expression of PTEN in U87MG 
cells eliminated PREX2 phosphorylation, and that the lipid phosphatase activity is 
required as the lipid phosphatase dead G129E mutant had no effect (Figure 2.8A). Since 
PTEN counteracts PI3K by reducing PI(3,4,5)P3 levels rather than directly regulating 
PI3K, this result demonstrated that PREX2 phosphorylation is dependent on a 
PI(3,4,5)P3 regulated kinase.  This conclusion was supported by a kinase assay showing 




Figure 2.9 – PI(3,4,5)P3 binding to a region in the DHPH domain of PREX2 is 
required for PREX2 phosphorylation A) Western blot analysis of PI(3,4,5)P3 
bead pull downs from HEK293 cells expressing V5 PREX2 or V5 PREX2 
ΔDHPH. B) Western blot analysis of V5 PREX2 or V5 PREX2 ΔDHPH 
expressing HEK293 cells that were starved and then treated with DMSO or 500nM 
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incubation with purified PI3K (Figure 2.8B). There did appear to be some baseline level 
of phosphorylation, but since PI3K inhibition had no effect, it is likely coming from a 
kinase that co-precipitates with PREX2, and not PI3K.  
To further support the idea that phosphorylation of PREX2 is PI(3,4,5)P3 
dependent, we blocked PI(3,4,5)P3 binding to PREX2 by removing the lipid binding PH 
domain, and then determined the effect on PREX2 phosphorylation. A construct of 
PREX2 lacking the DH and PH domains, hereafter called ΔDHPH, was overexpressed in 
HEK293 cells, and was unable to bind to PI(3,4,5)P3 beads or be phosphorylated at 
S1107, suggesting that PI(3,4,5)P3 binding is important for PREX2  
phosphorylation (Figure 2.9A, B).  To analyze the effect of PI(3,4,5)P3 binding in the 
full-length PREX2 protein, we attempted to disrupt PI(3,4,5)P3 binding with point 
mutations in the PH domain of PREX2. Previous studies have identified a PI(3,4,5)P3 
consensus binding sequence within PH domains which consists of a lysine at the second 
to last position in the PH domain β1 strand and an arginine or lysine at the second and 
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Figure 2.10 – Model of the PREX2 PH domain A) A ribbon diagram of the 
PREX2 PH domain model with the putative PI(3,4,5)P3 binding region identified. 
B) Predicted secondary structures of PREX2 PH domain from model. 
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fourth position from the beginning of the β2 strand (Isakoff et al., 1998; Park et al., 2008). 
Currently, there is no crystal structure of PREX2; however, we created a model of the 
PREX2 PH domain based on homology to known PH domain structures, and the potential 
residues that comprise the common PH domain secondary structures were identified 
(Figure 2.10A, B). The β1β2 loop of PREX2 from our model was aligned with the β1β2 
loop of two well-known PI(3,4,5)P3 binding proteins, AKT1 and PDK1. Critical residues 
for binding of AKT1 and PDK1 to PI(3,4,5)P3 have been identified, and these residues 
are highlighted in Figure 2.11A (Komander et al., 2004; Thomas et al., 2002). According 
to our model, PREX2 contains the conserved lysine in the β1 strand (K254), and has an 
arginine at the third position of the β2 strand (R263), and we hypothesized that these two 
residues could be critical for PREX2 binding to PI(3,4,5)P3. Indeed, mutation of either 
K254 or R263 to glutamate was sufficient to completely block the binding of PREX2 to 
PI(3,4,5)P3 beads (Figure 2.11A). Given that PI(3,4,5)P3 activates PREX2 GEF activity, 
we tested whether blocking PI(3,4,5)P3 binding to the β1β2 loop affected PREX2 
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function. To do this, we measured the ability of PREX2 WT and PREX2 R263E to 
stimulate RAC1 loading of radiolabeled GTPγS ([35S]GTPγS), a non-hydrolyzable analog 
of GTP. We found that the R263E mutation eliminated PI(3,4,5)P3 mediated stimulation 
of PREX2 GEF activity (Figure 2.11B). Importantly, both of these mutations also 
resulted in significantly reduced phosphorylation of PREX2 after insulin treatment 
(Figure 2.11C). These data confirm that insulin dependent phosphorylation of PREX2 
requires PI(3,4,5)P3 binding to the PH domain and that K254 and R263 surrounding the 






Figure 2.11 – PI(3,4,5)P3 binding to PREX2 and insulin-induced PREX2 
phosphorylation requires the β1β2 loop of the PREX2 PH domain A)  (Top) Western 
blot analysis of PI(3,4,5)P3 pull downs from HEK293 cells expressing either V5 PREX2 
WT, K254E, or R263E. (Bottom) Diagram showing the β1β2 loop region of the PREX2 
PH domain model aligned with the same region on PDK1 and AKT1. B) V5 PREX2 WT 
or R263E was purified from HEK293 cells and the ability of increasing doses of 
PI(3,4,5)P3 to stimulate PREX2 GEF activity towards GST RAC1 was assessed in an in 
vitro GEF assay. Data are mean ± standard deviation (SD) for at least two experiments 
with samples done in duplicate at each PI(3,4,5)P3 concentration, and * represents p < 
0.001 by t-test. C) Western blot analysis of starved or insulin treated HEK293 cells 
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Figure 2.12 – Gβγ stimulates phosphorylation of PREX2 A) Western blot 
analysis of starved HEK293 cells where V5 PREX2 was expressed with or without 
FLAG/HA Gβγ. B) Western blot analysis of HEK293 cells where V5 PREX2 was 
expressed with or without FLAG/HA Gβγ. Cells were then starved and treated with 
DMSO or 500nM GDC0941 followed by treatment with insulin. C) Western blot 
analysis of HEK293 cells where V5 PREX2 was expressed with or without 
FLAG/HA Gβγ. Cells were then starved and treated with DMSO or either 500nM or 
5μM BEZ235 followed by treatment with insulin. D) Western blot analysis of 
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Gβγ stimulates phosphorylation of PREX2  
Given that PREX2 is activated by PI(3,4,5)P3 and requires PI(3,4,5)P3 for 
phosphorylation, we hypothesized that phosphorylation of PREX2 may be associated 
with activation of PREX2 GEF activity. The second messenger Gβγ also activates 
PREX2, so we tested the effect of Gβγ on the phosphorylation of PREX2. We found that 
overexpression of Gβγ induced the phosphorylation of PREX2 in starved cells, further 
suggesting a link between PREX2 activation and phosphorylation (Figure 2.12A). 
Phosphorylation of PREX2 at S1107 was also increased by Gβγ. Further, Gβγ-induced 
phosphorylation of PREX2 was only mildly sensitive to PI3K inhibition by GDC0941 at 
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a concentration where insulin-induced phosphorylation of PREX2 and AKT was 
completely eliminated, indicating that phosphorylation mediated by Gβγ occurs primarily 
through a PI3K independent mechanism (Figure 2.12B). Given that Gβγ activates PI3Kγ 
and PI3Kβ independently of insulin receptor activation, and GDC0941 has a relatively 
high IC50 towards PI3Kγ, we tested a more effective PI3Kγ inhibitor, BEZ235 (Maira et 
al., 2008). This drug had a minimal effect on Gβγ-induced phosphorylation of PREX2 at 
very high doses, while ablating insulin dependent phosphorylation (Figure 2.12C). The 
mild effect of PI3K inhibitors on Gβγ-induced phosphorylation of PREX2 could be a 
result of eliminating the basal PI(3,4,5)P3 dependent phosphorylation that exists in 
starved cells, or there could be some cross-talk between Gβγ and certain PI3K isoforms. 
Further, as was the case with insulin dependent phosphorylation, PP1α expression 
eliminated phosphorylation of PREX2 that was stimulated by Gβγ (Figure 2.12D).  From 
these data, it is clear that increasing the levels of intracellular Gβγ is another mechanism 
to stimulate the phosphorylation of PREX2.   
 
DISCUSSION 
PREX2 is a PI(3,4,5)P3 and Gβγ dependent RAC GEF with established roles in 
the insulin signaling pathway (Donald et al., 2004; Hodakoski et al., 2014; Rosenfeldt et 
al., 2004). In this chapter, we describe the first reported instance of phosphorylation 
events occurring on PREX2. Our data show that PREX2 was phosphorylated after insulin 
receptor activation through a PI3K dependent mechanism. While phosphorylation of 
PREX2 was not regulated by the PI(3,4,5)P3 regulated kinases AKT, PDK1, and 
mTORC1, it required intact PREX2 binding to PI(3,4,5)P3. PREX2 phosphorylation was 
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also stimulated by Gβγ overexpression, suggesting phosphorylation of PREX2 occurs in 
the context of PREX2 GEF activation.  
Using a mass spectrometry approach, we identified many residues on PREX2 that 
were phosphorylated, some of which were only phosphorylated in stimulated conditions. 
After generating an antibody to PREX2 that was phosphorylated at S1107, S1107 was 
revealed as an insulin and Gβγ-induced phosphorylation site. While we followed up on 
S1107, our data would suggest that there are more sites that are induced by insulin and 
Gβγ. For example, when S1107 was mutated to alanine so that it could no longer be 
phosphorylated, there was a reduction in the insulin-induced upper band of PREX2, but it 
was not completely eliminated. In addition, as shown in Figure 2.5C, while S1107 was 
significantly enriched in the upper band of PREX2 compared to the total protein, the 
lower band was also phosphorylated to a small degree. If S1107 were the sole site 
responsible for the shift, then only the upper band should be phosphorylated. A better 
understanding of how PREX2 phosphorylation is regulated, which is addressed in 
Chapter 3, will be critical in designing future mass spectrometry experiments to more 
effectively identify relevant phosphorylation sites.  
Studies with PREX1 have shown that the region of the IP4P domain that is 
homologous to the region surrounding S1107 on PREX2 is important for the regulation 
of PREX1 by phosphorylation. The residue on PREX1 (S1169) that is homologous to 
S1107 on PREX2, was identified as one of the residues with elevated phosphorylation 
following growth factor treatment, including IGF (Montero et al., 2011; Montero et al., 
2013). In addition, many of the sites on PREX1 that are de-phosphorylated by PP1α are 
in this region, including the prominent site, S1165 (Barber et al., 2012). Importantly, the 
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kinase that phosphorylates PREX1 after treatment with growth factors and the kinase or 
kinases that phosphorylate the PP1α sensitive sites on PREX1 have not been identified. 
In Chapter 3, we attempt to identify the PREX2 kinase, and given the similarities 
between PREX1 and PREX2 phosphorylation, these studies have implications for 
PREX1 as well.  
We also found that phosphorylation of PREX2, including at S1107, was sensitive 
to PP1α and PP2A dephosphorylation. This is consistent with the presence of a PP1α 
binding site near S1107 and the previous reports showing that a fragment of PREX2 
containing this binding site can interact with PP1α  (Barber et al., 2012; Hendrickx et al., 
2009). Our data showed that PP1α can completely ablate insulin and Gβγ-induced 
phosphorylation of PREX2; however, it is still unclear how these dephosphorylation 
events are regulated downstream of insulin receptor or GPCR activation. PP1α 
dephosphorylation activates PREX1, and if this is also the case for PREX2, then it is 
possible that PP1α and PP2A are activated downstream of insulin receptor or GPCR 
activation to stimulate PREX2 (Barber et al., 2012). In this model, PREX2 would be held 
in an inactive conformation by a kinase that is constitutively active in a basal cellular 
state. However, our data would suggest that this model is unlikely given that PREX2 
appears to be dephosphorylated when cells are starved and then phosphorylated under 
conditions where PREX2 is activated.  A more likely model from our data would be that 
phosphatases are active in starved cells, keeping PREX2 dephosphorylated and primed 
for activation by PI(3,4,5)P3 or Gβγ. In this case, the function of phosphorylation is less 
clear, and could potentially be a mechanism to turn off PREX2 GEF activity after it has 
been activated by a signal. This is a possibility that will be explored in Chapter 3.  
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BACKGROUND AND SIGNIFICANCE 
 In Chapter 2, we showed that PREX2 is phosphorylated after insulin receptor 
activation, and that these phosphorylation events require PI3K and binding of PREX2 to 
PI(3,4,5)P3. We also found that PREX2 was phosphorylated downstream of Gβγ. Given 
that phosphorylation commonly regulates the function of other GEFs, including PREX1, 
we hypothesized that it was important for PREX2 function as well. Further, PREX2 has a 
functional role in insulin signaling in the mouse, suggesting that regulation of PREX2 
function by phosphorylation downstream of insulin stimulation could have important 
cellular consequences for glucose metabolism. In this chapter, we analyze the effect of 
phosphorylation on PREX2 function, and use clues from our functional studies to identify 
the PREX2 kinase.  
RESULTS 
Phosphorylation of PREX2 prevents membrane binding  
RAC1, the target of PREX2 GEF activity, is activated at the membrane, and 
further, membrane bound PREX1 is more active than cytosolic PREX1 (Barber et al., 
2007). This suggests that alterations in the ability of PREX2 to bind to the membrane 
could have important implications for its function. To determine whether phosphorylation 
of PREX2 alters membrane binding, we performed cellular fractionation on V5 PREX2 
expressing cells. After insulin or Gβγ stimulation, both the phosphorylated and 
dephosphorylated forms of PREX2 were present in the cytoplasmic fraction (Figure 
3.1A). Importantly, only the dephosphorylated form of PREX2 was present in the 
membrane fraction, indicating that the phosphorylated form of PREX2 is unable to bind 




Figure 3.1 – Phosphorylation of PREX2 prevents membrane localization A) 
Western blot analysis of cytosolic and membrane fractions from starved or insulin 
treated HEK293 cells expressing V5 PREX2 with or without co-expression of 
FLAG/HA Gβγ. B) Western blot analysis of GST PTEN pull downs of endogenous 
PREX2 from cytosolic and membrane fractions of HEK293 cells. Cells were 
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Insulin (min):     0          2         30         0           2         30
we performed GST PTEN pull downs from the membrane and cytosolic fractions of 
HEK293 cells in order to isolate PREX2 and obtain a clear Western blot signal. As seen 
with V5 PREX2, phosphorylated endogenous PREX2 was not at the membrane, despite 
being present in the cytoplasm (Figure 3.1B). These data show that phosphorylation 
prevents PREX2 from binding to the membrane where it can stimulate RAC1, suggesting 
that phosphorylation may negatively regulate PREX2 function.  
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Phosphorylation of PREX2 blocks binding to PI(3,4,5)P3 and Gβγ  
Both PI(3,4,5)P3 and Gβγ are membrane-associated, so we hypothesized that 
phosphorylated PREX2 may have reduced affinity for PI(3,4,5)P3 and Gβγ, resulting in 
the localization patterns we observed. PI(3,4,5)P3 pull downs of V5 PREX2 were 
performed from insulin stimulated or Gβγ expressing cells, and we found that the 
phosphorylated form of PREX2 was completely absent from the pull down, suggesting 
that phosphorylation was preventing PREX2 from binding to PI(3,4,5)P3 (Figure 3.2A). 
In Chapter 1, we established that endogenous PREX2 is stoichiometrically 
phosphorylated by an insulin dependent signal in HEK293 cells.  Given that finding, it 
was not surprising that the effect of insulin stimulation on PI(3,4,5)P3 binding was even 
more striking with endogenous PREX2, as insulin significantly reduced the ability of 
PREX2 to bind to PI(3,4,5)P3, an effect that was reversed with PI3K inhibition (Figure 
3.2B).  In addition, PI(3,4,5)P3 pull-downs were performed with V5 PREX2 from cells 
where PP1α was co-expressed in order to generate the least phosphorylated form of 
PREX2, or from cells treated with calyculin A to generate a maximally phosphorylated 
form of PREX2 (Figure 3.2C). The result was clear as PP1α co-expression increased the 
ability of PREX2 to bind PI(3,4,5)P3, and calyculin A treatment almost completely 
ablated PI(3,4,5)P3 binding. Further, in the calyculin A treated sample, while almost all 
of the PREX2 in the input was enriched in the slower migrating, phosphorylated form of 
PREX2, the small amount that did bind to PI(3,4,5)P3 was the faster migrating, 
dephosphorylated form. This result also showed that phosphatases can regulate PREX2 
binding to PI(3,4,5)P3. One alternative explanation for our results could be that the 




Figure 3.2 – Phosphorylation of PREX2 blocks binding to PI(3,4,5)P3  A) Western 
blot analysis of PI(3,4,5)P3 pull downs from starved or insulin treated HEK293 cells 
expressing V5 PREX2 with or without FLAG/HA Gβγ. B) Western blot analysis of 
endogenous PREX2 isolated from HEK293 cells with either PI(3,4,5)P3 beads (top) or 
PREX2 antibody (bottom). C) Western blot analysis of PI(3,4,5)P3 pull downs from V5 
PREX2 expressing cells with either V5 PP1α co-overexpression or treatment with 100nM 
calyculin A. D) Western blot analysis of PI(3,4,5)P3 pull downs from V5 PREX2 
expressing cells that were starved and treated with either 500nM GDC0941 or 100nM 
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dephosphorylated form, and we  only see binding of dephosphorylated PREX2 to 
PI(3,4,5)P3 in vitro because endogenous PI(3,4,5)P3 is binding all of the phosphorylated 
protein. However, considering calyculin A-treated PREX2 could not bind to PI(3,4,5)P3 




Figure 3.3 – Phosphorylation of PREX2 blocks binding to Gβγ, but not 
other known PREX2 interacting proteins  A) Western blot analysis of FLAG 
immunoprecipitations from HEK293 cells co-expressing FLAG/HA Gβγ and 
V5 PREX2 with and without 100nM calyculin A treatment. B) Western blot 
analysis of pull downs with GST PTEN, GST PP1α, GST RAC1, or PI(3,4,5)P3 
beads from HEK293 cells expressing V5 PREX2 with or without FLAG/HA 
Gβγ.  The cells were starved and treated with insulin or 100nM calyculin A. U - 


































low), it is more likely that phosphorylated PREX2 has a lower affinity for PI(3,4,5)P3 
(Figure 3.2D).     
 Next, we tested whether phosphorylation of PREX2 affected its ability to bind to 
Gβγ. Co-immunoprecipitation of V5 PREX2 and FLAG-Gβγ with a FLAG antibody 
showed that the dephosphorylated and faster migrating species of PREX2 preferentially 
bound to Gβγ (Figure 3.3A). Phosphorylating PREX2 even further with calyculin A 
treatment reduced overall binding of PREX2 and Gβγ. These data show that 
phosphorylation of PREX2 reduces binding to Gβγ. To determine whether 
phosphorylation prevented binding of PREX2 to other known interacting partners, we 
performed pull downs with GST tagged PTEN, PP1α, and RAC1. While PI(3,4,5)P3 only 
bound the dephosphorylated form of PREX2, RAC1 and PTEN did not discriminate 
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between any forms of PREX2 (Figure 3.3B). The dephosphorylated form of PREX2 was 
somewhat enriched in the PP1α pull downs (though not as much as in the PI(3,4,5)P3 pull 
downs), but this was likely because PP1α was dephosphorylating PREX2 during the 
reaction. These findings suggest that phosphorylation selectively blocks binding of 
PREX2 to PI(3,4,5)P3 and Gβγ.  
Phosphorylation of PREX2 reduces PI(3,4,5)P3 and Gβγ activation of GEF activity 
Given that phosphorylation blocked PREX2 binding to PI(3,4,5)P3 and Gβγ, it 
was then important to determine the effect of phosphorylation on PI(3,4,5)P3 and Gβγ 
stimulation of GEF activity. V5 PREX2 was purified from HEK293 cells after being 
treated with either GDC0941, insulin in combination with Gβγ co-expression, or 
calyculin A, to achieve relatively dephosphorylated, partially phosphorylated, and 
maximally phosphorylated states of PREX2, respectively (Figure 3.4A). When compared 
to dephosphorylated PREX2, partially phosphorylated PREX2 showed decreased 
activation of GEF activity at multiple PI(3,4,5)P3 concentrations, while activation of the 
maximally phosphorylated form of PREX2 was reduced even further (Figure 3.4B). In 
addition, Gβγ dependent stimulation of PREX2 GEF activity was similarly affected by 
phosphorylation across many Gβγ concentrations (Figure 3.4C).  We next sought to 
determine whether this negative regulation by phosphorylation was important in cells, 
and to probe this, we used a mutant containing a phospho-mimicking glutamate mutation 
at S1107 (S1107E) on PREX2. Previous studies from our lab demonstrated that PREX2 
expression in BT549 breast cancer cells stimulates invasion through matrigel. 
Importantly, the S1107E mutation reduced the ability of PREX2 to stimulate invasion in 




Figure 3.4 – Phosphorylation of PREX2 reduces PREX2 GEF activity A) V5 PREX2 
was expressed in HEK293 cells with or without co-expression of FLAG/HA Gβγ and then 
was purified after being treated with either 500nM GDC0941, insulin (with co-expression 
of FLAG/HA Gβγ), or 100nM calyculin A. B and C) The ability of increasing doses of 
PI(3,4,5)P3 in (B) or Gβγ in (C) to stimulate PREX2 GEF activity towards GST RAC1 
was assessed in an in vitro GEF assay. Data at each PI(3,4,5)P3 and Gβγ concentration are 
mean ± SD for 3 experiments and # represents p < 0.05 for GDC0941 vs. Gβγ/Insulin, and 
* represents p < 0.005 for GDC0941 vs. calyculin A by t-test. D) V5 PREX2 WT or 
S1107E were expressed in BT549 cells and invasion assays were performed. 
















































































































reduces GEF activity (Figure 3.4D).  Analysis of the time course of insulin-induced 
phosphorylation of PREX2 revealed that phosphorylation of both endogenous PREX2 
and transfected V5 PREX2 did not peak until the 30 minute time point (Figure 3.5A, B). 
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Figure 3.5 – Time course of PREX2 phosphorylation A) Western blot analysis of 
endogenous PREX2 that was immunoprecipitated from HEK293 cells that were starved 
and treated with insulin for the indicated times. B) Western blot analysis of V5 PREX2 
expressing HEK293 cells that were starved and then treated with insulin for the indicated 
times. For quantification of phosphorylation, intensity of band was normalized to total 
protein of that sample. The highest value was set to 1, and the remaining samples were 
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This is in contrast to phosphorylation of the PI(3,4,5)P3 dependent kinase AKT, which is 
highly phosphorylated within the first 30 seconds after insulin treatment, and peaks 
between 1-5 minutes. This delayed time course of PREX2 phosphorylation, in 
combination with our data showing that phosphorylation reduces GEF activity and 
PREX2 stimulated invasion, supports a model where phosphorylation occurs after 




Figure 3.6 – RAC1 GTP loading and PREX2 GEF activity are required for 
phosphorylation of PREX2 A) Western blot analysis of starved or insulin treated 
HEK293 cells expressing V5 PREX2 with or without MYC RAC1 WT or the 
dominant negative mutant T17N. B) Western blot analysis of starved or insulin 
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RAC1 promotes PAK phosphorylation of PREX2  
Our data suggest that PREX2 phosphorylation is part of negative feedback 
following RAC1 activation to decrease PREX2 GEF activity and allow for tight control 
of the RAC1 signal. If this were true, then higher RAC1 activity within the cell should 
increase phosphorylation of PREX2. Indeed, expression of RAC1 in HEK293 cells 
induced phosphorylation of PREX2 even in the absence of insulin (Figure 3.6A).  The 
dominant negative mutant T17N RAC1 mutant did not increase PREX2 phosphorylation, 
and further, the T17N mutant blocked the insulin stimulated phosphorylation, indicating 
that RAC1 is downstream of PI(3,4,5)P3 generation. In addition, a GEF dead PREX2 
mutant (E30A/N212A) was not phosphorylated following insulin treatment, confirming 
that PREX2 must be able to stimulate RAC1 in order to become phosphorylated (Figure 
3.6B) (Mense et al., 2015). These results suggested that the kinase or kinases that are 




Figure 3.7 – Inhibition of PAK kinases blocks the phosphorylation of PREX2 
A) Western blot analysis of V5 PREX2 expressing HEK293 cells that were starved 
and then treated with DMSO or varying concentrations of the pan-PAK inhibitor 
PF-3758309 followed by insulin treatment.  B) Western blot analysis of HEK293 
cells expressing V5 PREX2 with or without Gβγ. Cells were starved and treated 








- + + + +









- + + + +
0 0 1 10 20
 
Figure 3.8 – PREX2 is a direct substrate of PAK1 in vitro and PAK1 increases 
phosphorylation in cells A) In vitro kinase assay with purified PAK1 and V5 
PREX2 isolated on V5 agarose beads, performed with or without PF-3758309. 
Incorporation of [γ-32P]-ATP was analyzed. B) A) Western blot analysis of starved 
or insulin treated HEK293 cells expressing V5 PREX2 with or without MYC 
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The PAK family of kinases, consisting of group I PAKs (PAK1-3) and group II 
PAKs (PAK4-6), are important mediators of signaling downstream of RHO family 
GTPases. The regulation of PAK1 is best understood, and its kinase activity is activated 
downstream of insulin and upon binding to GTP bound RAC1, making it a candidate 




Figure 3.9 – PREX2 is a direct substrate of PAK4 in vitro and PAK4 increases 
phosphorylation in cells A) In vitro kinase assay with purified PAK4 and V5 
PREX2 isolated on V5 agarose beads, performed with or without PF-3758309. 
Incorporation of [γ-32P]-ATP was analyzed.  B) Western blot analysis of starved 
HEK293 cells expressing V5 PREX2 with or without MYC PAK4. 
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of PAKs with the inhibitor PF-3758309 blocked the insulin and Gβγ-induced 
phosphorylation of PREX2 (Figure 3.7A, B). As is the case for many small molecule 
inhibitors of kinases, they are likely not entirely specific for their proposed target kinase. 
So we then tested whether specific isoforms of PAK kinases could regulate PREX2 
phosphorylation with in vitro kinase assays and overexpression of PAK isoforms in cells. 
We first asked whether PREX2 was a direct substrate of PAK1 and found that PREX2 
was indeed phosphorylated by PAK1 in vitro (Figure 3.8A). To determine whether PAK1 
can affect PREX2 phosphorylation in cells, we overexpressed PAK1 in HEK293 cells 
and analyzed the effect on PREX2 phosphorylation. Overexpression of PAK1 induced 
the phosphorylation of PREX2, and the induction of the PREX2 mobility shift was even 
more striking with the constitutively active PAK1 mutant T423E (Figure 3.8B). The 
kinase dead and dominant negative PAK1 mutant K299R completely eliminated any 
phosphorylation of PREX2 in either the starved or insulin treated contexts. Interestingly, 
purified PAK4 was also able to phosphorylate PREX2 in vitro and increase 




Figure 3.10 – PAK1 phosphorylation reduces 
PREX2 GEF activity PREX2 was purified from 
HEK293 cells co-expressing either MYC PAK1 WT 
or K299R. The ability of increasing doses of 
PI(3,4,5)P3 to stimulate GEF activity towards GST 
RAC1 was assessed in an in vitro GEF assay. Data 
are mean ± SD for two experiments with samples 
done in triplicate at each PI(3,4,5)P3 concentration 






































the functional data in Figure 3.4, PAK1-induced phosphorylation also reduced PREX2 
GEF activity towards RAC1 (Figure 3.10). PREX2 that was purified from cells co-
expressing PAK1 had lower GEF activity towards RAC1 over multiple PI(3,4,5)P3 
concentrations compared to 
PREX2 purified from cells 
co-expressing dominant 
negative PAK1. Taken 
together, these data show 
that RAC1 activates PAK 
kinases to initiate this 
negative regulation of 
PREX2 GEF activity 
following insulin and Gβγ 
stimulation.  
In summary, the data 
from chapters 2 and 3 
outline a novel signaling pathway downstream of insulin receptor and Gβγ dependent 
activation of PREX2 where PAK kinases, which are activated by RAC1, phosphorylate 
PREX2 to reduce its GEF activity. Altogether, we propose that PREX2 is 
dephosphorylated in an unstimulated cell, and then upon binding of insulin or a GPCR 
agonist to its receptor, PI(3,4,5)P3 or Gβγ levels increase and dephosphorylated PREX2 
can bind these molecules on the membrane and activate RAC1 (Figure 3.11). Higher 



























release it from the membrane, decreasing RAC1 activation. Additionally, either PP1α or 
PP2A can complete the circuit by dephosphorylating PREX2, priming it for future 
activation by PI(3,4,5)P3 or Gβγ. This model allows for tight regulation of the length and 




It has previously been reported that PI(3,4,5)P3 and Gβγ can activate PREX2, and 
as we described in Chapter 2, these two molecules also stimulate PREX2 
phosphorylation. Here we uncovered the functional consequences of these 
phosphorylation events. We first found that PREX2 phosphorylation blocked the 
translocation of PREX2 to the cell membrane, and prevented binding to PI(3,4,5)P3 and 
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Gβγ. There are important parallels between our findings and PREX1 studies that 
analyzed the relationship between phosphorylation and membrane binding, which could 
inform future experiments involving PREX2. As mentioned in Chapter 1, in vitro binding 
of PREX1 to Gβγ is reduced by PKA phosphorylation, and agents that increase cAMP, 
and therefore activate PKA, decrease PREX1 levels at the membrane (Urano et al., 2008; 
Zhao et al., 2007). Further, it was reported that PREX1 requires certain intramolecular 
interactions to bind to Gβγ, and these intramolecular interactions are disrupted by PKA 
phosphorylation, blocking PREX1 binding to Gβγ (Urano et al., 2008). The 
phosphorylation events identified here on PREX2 do not appear to be mediated by PKA; 
however, it is possible that PAK1 phosphorylation of PREX2 could be reducing 
PI(3,4,5)P3 and Gβγ binding through a similar mechanism, by preventing intramolecular 
interactions. Intramolecular interactions have also been shown to regulate GEF activity of 
other RHO family GEFS, such as DBL and VAV1 (Aghazadeh et al., 2000; Bi et al., 
2001). 
We also found that phosphorylation of PREX2 not only blocked binding to 
PI(3,4,5)P3 and Gβγ, but it prevented activation by these second messengers. Further, a 
phospho-mimicking mutation at S1107 reduced PREX2 stimulated invasion. These data 
suggest that phosphorylation is part of a negative feedback circuit initiated by PREX2 
activation of RAC1. The time course of PREX2 phosphorylation was delayed compared 
to AKT, which is also consistent with phosphorylation functioning to attenuate PREX2 
function after it has been activated.  The mechanisms of RAC1 inactivation are generally 
not as well characterized as the mechanisms of RAC1 activation, especially after insulin 
stimulation, and negative feedback circuits like the one identified here could be a 
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significant and more commonly utilized mechanism within the cell to control the time 
course of RAC1 activation (Wertheimer et al., 2012).   
 Furthermore, we discovered that PREX2 was a substrate of the RAC1 dependent 
PAK family of kinases. These kinases are well known for their role in propagating RAC1 
dependent outputs. Given this role, it is unexpected for PAK kinases to mediate negative 
feedback to turn off RAC1 activity. However, there is precedent for this in lower 
eukaryotes. In the yeast Saccharomyces cerevisiae, the Pak family member Cla4 
phosphorylates Cdc24, a GEF for the Cdc42 GTPase, and phosphorylation reduces GEF 
activity in vitro and reduces levels of Cdc42 at the front of a cell during polarization 
(Bose et al., 2001; Gulli et al., 2000; Kuo et al., 2014). Further, in the fungus Ustilago 
maydis, where Cdc24 is also a Rac1 GEF, Cla4 phosphorylates Cdc24, causing its 
degradation and a reduction in Rac1 activation (Frieser et al., 2011). Here, we show that 
this type of PAK mediated negative regulation of GEFs occurs in higher eukaryotes as 
well.  
The mode of regulation identified in this chapter, where a pathway evolves a 
mechanism to turn a signal off after it has been activated, has been reported previously in 
mammalian cells, including within the insulin signaling pathway. For example, 
mTORC1, an important effector of insulin signaling, also initiates negative feedback to 
reduce activation of the pathway. Insulin activation of mTORC1 leads to the stimulation 
of various downstream kinases to regulate protein synthesis. However, mTORC1 
activation also results in serine phosphorylation of IRS proteins, reducing their stability 
and decreasing the insulin signal. IRS protein levels can then be restored upon pathway 
inactivation caused by PTEN expression or PI3K inhibition (Harrington et al., 2004; 
74 
   
Haruta et al., 2000; Simpson et al., 2001; Takano et al., 2001). Importantly, mTORC1 
dependent regulation of IRS stability appears to be a critical consideration for 
therapeutics given that inhibition of mTORC1 leads to increased AKT phosphorylation in 
cancer cell lines and human patients, which may partially explain the modest effects of 
these inhibitors in cancer patients (O'Reilly et al., 2006).  
The role of mTORC1 in insulin signaling is very similar to the model we propose 
for PAK kinases, where PAK can both propagate the insulin dependent RAC1 signal and 
negatively regulate it through PREX2. Furthermore, similar to mTORC1 dependent 
negative feedback, PAK phosphorylation of PREX2 could have important therapeutic 
implications. PAK inhibitors are currently being evaluated as cancer therapeutics, and if 
PAK negative regulation of PREX2 is playing a significant role in insulin signaling, or 
more generally in RAC1 activation, then it may be important to consider in the context of 
certain cancers (Baker et al., 2014). For example, a tumor with PREX2 overexpression 
may not respond well to PAK inhibitors due to an increase in PREX2 GEF activity 
towards RAC1. Further, given the role of PREX2 in cancer, it will be important to study 
PAK mediated inactivation of PREX2 not only in the context of resistance to 
therapeutics, but in tumorigenesis. Many PREX2 mutations have been identified in 
different types of cancer, and it is possible that some of these could disrupt the PAK1 
dependent negative feedback and activate RAC1 signaling, a possibility we will explore 
in Chapter 4.    
PREX2 has previously been identified as a critical mediator of insulin signaling, 
and our data showing that PREX2 function is tightly regulated by insulin-induced 
phosphorylation further supports this idea (Hodakoski et al., 2014). Future experiments 
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should focus on the effect of this feedback circuit on both PREX2 and RAC1 dependent 
physiological outputs downstream of insulin receptor activation, including glucose 
metabolism. It will also be of interest to study this signaling pathway in the context of 
insulin related disease, such as diabetes. PREX2 protein expression appears to be lower 
in adipose tissue of insulin resistant human patients, suggesting that reducing PREX2 
activity to prevent glucose uptake is a possible mechanism for insulin resistance 
(Hodakoski et al., 2014). In addition, the importance of RAC1 in insulin resistance is 
highlighted by the fact that RAC1 activity can be decreased in muscle tissue of insulin 
resistant mice and humans (Sylow et al., 2013; Sylow et al., 2014).  Our data present the 
possibility that a reduction in PREX2 GEF activity and RAC activation could also be 
achieved through PAK mediated phosphorylation, meaning phosphorylation of PREX2 
could be altered in diabetes and could potentially be a cause of insulin resistance. High or 
chronic levels of insulin (in addition to GPCR-activating fatty acids) could lead to 
activation of PAK phosphorylation of PREX2, keeping PREX2 inactive and potentially 
disrupting insulin signaling. Interestingly, the activation of feedback mechanisms in 
insulin resistance has been identified previously, including mTORC1 dependent 
ribosomal S6K phosphorylation of IRS1 (Pende et al., 2000; Um et al., 2004). 
Our findings in this chapter could also have important implications for PREX1. In 
this study, we identified S1107 as an insulin, Gβγ, and PAK sensitive phosphorylation 
site. Interestingly, the residue on PREX1 (S1169) that is phosphorylated following 
treatment with neuregulin and IGF is the homologous residue to S1107 (Montero et al., 
2011; Montero et al., 2013). In addition, PP1α dephosphorylation of PREX1 activates its 
GEF activity, which is consistent with our model for PREX2 (Barber et al., 2012). Lastly, 
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PI3K and Gβγ co-expression in sf9 insect cells leads to an electrophoretic mobility shift 
of PREX1, and the slower migrating, presumably phosphorylated species of PREX1 is 
mostly excluded from the membrane fraction (Barber et al., 2007). The similarities 
between phosphorylation events on PREX1 and PREX2 suggest PREX1 may also be 
regulated by PAK phosphorylation.  
 Collectively, our data represent a novel paradigm for maintaining a tightly 
regulated RAC1 signal by blocking the stimulation of the specific GEF that was 
activated, in this case PREX2. This type of regulation adds a layer of complexity to the 
current model where RAC1 is activated by GEFs and inactivated by GAPs and GDIs, and 
if PAK kinases regulate other GEFs the same way, then this signaling pathway could 
have implications in many aspects of cellular physiology. 
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BACKGROUND AND SIGNIFICANCE  
The important role of PREX2 in cancer is evidenced by the fact that PREX2 
expression is increased in many different tumor types and that it is one of the most 
commonly mutated GEFs in cancer. PREX2 tumor mutations are spread throughout the 
entire length of the protein and do not cluster in any particular region, making it difficult 
to hypothesize the potential functional consequences of these mutations (Cerami et al., 
2012; Gao et al., 2013). Two studies have analyzed the effect of PREX2 tumor mutations 
on its function and oncogenicity. In a study by Berger et al., a number of PREX2 
mutations found in melanoma were analyzed, and they showed that overexpression of 
K278*, E824*, Q1430*, or G844D PREX2 cooperate with NRAS to accelerate 
tumorigenesis in a melanocyte xenograft mouse model (Berger et al., 2012). Another 
study from our lab has shown that the G844D mutant, along with P948S from melanoma, 
and V432M from pancreatic cancer, are able to avoid inhibition of in vitro GEF activity 
by PTEN. Further, PTEN is unable to inhibit invasion stimulated by these three PREX2 
tumor mutants in BT549 breast cancer cells (Mense et al., 2015). These studies show that 
PREX2 tumor mutations are likely selected in cancer to give cells a tumorigenic 
advantage.   
However, given the large number of PREX2 mutations that have been reported, 
we still know relatively little about why the vast majority of these mutations are selected 
in cancer. In Chapters 2 and 3, we identified PAK mediated phosphorylation of PREX2 
downstream of RAC1 activation, and we showed that these phosphorylation events 
reduced PREX2 GEF activity. Here, we investigate the possibility that PAK dependent 





Figure 4.1 - Landscape of PREX2 tumor mutations (figure adapted from cBio web portal) 
A) Histogram of PREX2 showing current landscape of tumor mutations. B) Table showing 
the total number of reported cases for each PREX2 tumor mutant that was selected for further 






Mutation #of Occurrences Tumor Types
R155W/Q 5 Breast, Uterine, Leukemia, Colorectal, Stomach
R297C/H 6 Melanoma (4), Pancreas, Colorectal
R299Q 2 Prostate, Stomach
R363Q/W 7 Breast (3), Lung, Uterine, Colorectal, Sarcoma
common PREX2 tumor mutations have altered PAK phosphorylation and RAC1 GEF 
activity. 
RESULTS 
PREX2 hotspot tumor mutations reduce insulin and PAK1 mediated phosphorylation 
The published experiments that analyzed the functional consequences of PREX2 
tumor mutations occurred early on in the generation of The Cancer Genome Atlas and the 
cBio web portal, which made publically available a wealth of whole genome sequencing 
data from many different tumor types. Because of this, these studies on specific PREX2 
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tumor mutants were forced to use the limited data sets that were available at the time in 
choosing their mutations to study. Currently, over 700 mutations on PREX2 in many 
different types of cancer have been reported. This allowed us to identify recurrent, or “hot 
spot” mutations, that are more likely to have important functional alterations that are 
selected for by the tumor. Using the cBio portal to analyze the reported PREX2 
mutations, we selected three of the most common somatic tumor missense mutations to 
study: R155W, R297C, and R363Q (Figure 4.1A) (Cerami et al., 2012; Gao et al., 2013). 
We also studied R299Q because it was another arginine that was just two amino acids 
away from a common missense mutation, R297C, and was also mutated in two separate 
tumor samples. R155W is in the catalytic DH domain, while R297C, R299Q, and R363Q 
are in the PH domain. These mutations are found in a variety of human cancers (Figure 
4.1B). 
First, the effect of insulin stimulation on the phosphorylation of these mutants was 
determined in HEK293 cells. All four mutants, R155W, R297C, R299Q, and R363Q had 
reduced phosphorylation compared to wild type PREX2. Phosphorylation of R297C and 
R299Q was almost completely ablated, while the reduction of phosphorylation on 
R155W and R363Q was more subtle (Figure 4.2A). In response to PAK1 overexpression, 
we observed a very similar pattern of reduced phosphorylation of these four tumor 
mutants (Figure 4.2B). Taken together, these data show that insulin and PAK1 dependent 
phosphorylation of PREX2 hotspot tumor mutations was reduced, particularly in the case 




Figure 4.2 – PREX2 hotspot mutations have reduced levels of phosphorylation 
A) Western blot analysis of starved or insulin treated HEK293 cells expressing V5 
PREX2 WT, R155W, R297C, R299Q, or R363Q. B) Western blot analysis of 
starved HEK293 cells expressing V5 PREX2 WT, R155W, R297C, R299Q, with or 
without co-expression of MYC PAK1 R363Q. 
V5 PREX2 WT WT          R155W        R297C      R299Q      R363Q




V5 PREX2 WT WT          R155W        R297C      R299Q      R363Q





Phosphorylation of PREX2 R297C induced by activating PI3K tumor mutants is 
reduced  
PI3K is frequently mutated in cancer, particularly in breast cancer, and two hot 
spot mutations, E545K in the helical domain and H1047R in the kinase domain, have 
been shown to activate PI3K kinase activity, increase phosphorylation of downstream 
kinases such as AKT, promote anchorage independent cell growth, and cause tumor 
formation in mice (Cerami et al., 2012; Gao et al., 2013; Ikenoue et al., 2005; Isakoff et 
al., 2005; Kang et al., 2005; Koren and Bentires-Alj, 2013; Zhao et al., 2005). Given that 
PREX2 can cooperate with the E545K activating mutant of PI3K to promote colony 




Figure 4.3 – R297C mutant has reduced phosphorylation after expression 
of PI3K activating mutations Western blot analysis of starved U87MG cells 
expressing V5 PREX2 WT, R155W, R297C, R299Q, or R363Q with or without 
co-expression of p110α H1047R or E545K. 
H1047R
E545K
V5 PREX2 WT WT          R155W        R297C      R299Q      R363Q







Figure 4.4 – R297C mutant does not efficiently bind PI(3,4,5)P3, but retains 
ability to bind cellular membrane A) Western blot analysis of PI(3,4,5)P3 pull 
downs from HEK293 cells expressing V5 PREX2 WT, R155W, R297C, R299Q, 
or R363Q. B) Western blot analysis of cytosolic and membrane fractions from 
HEK293 cells expressing V5 PREX2 WT, R263E, R297C, or R299Q.  
had decreased phosphorylation when co-expressed with these PI3K mutants. 
Interestingly, in U87MG cells, only the R297C mutant showed significantly reduced 
phosphorylation (as shown by the extent of the PREX2 electrophoretic mobility shift) 
when co-expressed with either the H1047R or E545K PI3K mutants (Figure 4.3). The 
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R299Q mutant, which had comparable reductions in phosphorylation to R297C in 
response to insulin and PAK1 overexpression, had only a minor decrease in PI3K 
dependent phosphorylation. Further, a PI(3,4,5)P3 bead pull down showed that the 
R297C mutation significantly reduced PI(3,4,5)P3 binding, while PI(3,4,5)P3 binding to 
the other three PREX2 tumor mutants was unaffected (Figure 4.4A). This result could 
potentially explain why the R297C mutant is particularly susceptible to phosphorylation 
defects downstream of PI3K activation. When HEK293 cells expressing R297C were 
subjected to cell fractionation, this mutant was still present on the membrane (Figure 
4.4B). Further, the mutant that cannot bind PI(3,4,5)P3, R263E, was also present on the 
membrane, suggesting that PREX2 can bind to the membrane through PI(3,4,5)P3 
independent mechanisms. This is important because it suggests that R297C may still be at 
the membrane to activate RAC1, or inhibit PTEN, even though it cannot bind to 




Figure 4.5 – Consensus phosphorylation motif for PAK kinases figure adapted 
from (Rennefahrt et al., 2007).  
T158 on PREX2 is a potential PAK1 site that is altered in cancer 
Previous studies have identified PAK consensus phosphorylation motifs for the 
different isoforms of the kinase, and all of these motifs contain arginine residues at 
positions directly upstream of the phosphorylation site (Figure 4.5) (Rennefahrt et al., 
2007). Given that all of the recurrent tumor mutants we studied are on arginine residues, 
we hypothesized that mutating them in cancer is a mechanism to disrupt nearby PAK 
phosphorylation events, resulting in a more prolonged PREX2 GEF activation. 
Interestingly, R155W is directly upstream of T158, while R297C and R299Q are 
upstream of T302, supporting the possibility that these tumor mutants are reducing PAK 
phosphorylation by affecting PAK phosphorylation at these residues (Figure 4.6A). 





Figure 4.6 – T158 is a potential PAK 
phosphorylation site targeted by tumor mutation A) 
Sequences surrounding potential PAK phosphorylation 
sites downstream of hotspot PREX2 tumor mutations 
B) Western blot analysis of starved HEK293 cells 
expressing V5 PREX2 WT, T158A, T302A, S1107A, 
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similar extent as the 
corresponding tumor 
mutant, R155W, while an 
alanine mutation at T302 
had a minimal effect on 
phosphorylation, which is 
quite different from the clear 
reduction of R297C and 
R299Q phosphorylation 
(Figure 4.6B). From this 
data, it is possible that T158 
could be an additional 
PAK1 site; however, R297C 
and R299Q are likely 
reducing phosphorylation 
through some alterative mechanism. 
 
PREX2 tumor mutants have altered GEF activity towards RAC1 
We then analyzed the functional consequences of these tumor mutations by 
determining their ability to be stimulated by either PI(3,4,5)P3 or Gβγ. PI(3,4,5)P3 was 
able to activate the GEF activity of the tumor mutants; however, the level of stimulation 
was reduced with all four mutants when compared to wild type PREX2 (Figure 4.7A). 




Figure 4.7 – Tumor mutants have altered PI(3,4,5)P3 and Gβγ stimulated GEF activity 
in vitro A and B) WT PREX2 and the tumor mutants were purified and the ability of 0.1μM 
PI(3,4,5)P3 (A) or 0.5μM Gβγ (B) to stimulate PREX2 GEF activity towards RAC1 was 
measured. Data are mean ± SD for two experiments with samples done in duplicate at each 
PI(3,4,5)P3 concentration and * represents p < 0.001 by t-test.  C) V5 PREX2 WT or S1107E 
were expressed in BT549 cells and invasion assays were performed. Representative shown of 
























































































































type PREX2, while R155W and R363Q stimulation by Gβγ was reduced (Figure 4.7B). 
We then tested the ability of R297C to stimulate invasion in BT549 breast cancer cells. 
We found the R297C was still able to stimulate invasion towards an FBS gradient, 
suggesting that it is still a functional GEF in cells (Figure 4.7C). Taken together, the 
PI(3,4,5)P3 and Gβγ stimulated RAC1 GEF activity of these particular recurrent PREX2 
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tumor mutants is altered, and surprisingly was often lower than that of the wild type 
protein. 
DISCUSSION 
The data from this chapter show that phosphorylation of PREX2 is altered in the 
four recurrent tumor mutants that we analyzed: R155W, R297C, R299Q, and R363Q. 
Phosphorylation was reduced for all mutants in response to both insulin stimulation and 
PAK1 overexpression. Two of the mutants that are located in the PH domain, R297C and 
R299Q, had almost no detectable phosphorylation in both of these contexts, while 
phosphorylation of R155W or R363Q was only slightly reduced. These results are 
exciting when put in the context of our data presented in Chapters 2 and 3 where we 
identified PAK phosphorylation as a negative regulatory event to reduce PREX2 GEF 
activity towards RAC1. The reduced phosphorylation of these tumor mutants presents the 
possibility that cancer cells are escaping PAK mediated negative regulation of PREX2 
through mutations. This would be advantageous for a tumor cell, potentially prolonging 
RAC1 activation following insulin or GPCR stimulation, leading to a more invasive cell.  
We also found that R297C had reduced phosphorylation when co-expressed with 
the constitutively activate PI3K mutations, E545K and H1047R. Given the prevalence 
and potency of these PI3K mutations in cancer, a PREX2 mutant that can avoid 
inactivation by PAK following PI3K-mediated PI(3,4,5)P3 generation could be especially 
advantageous for a tumor cell. Further, since PREX2 cooperates with activating PI3K 
mutations to form colonies in soft agar, it would not be surprising for a tumor cell to 
evolve a mechanism where it enhanced this cooperation through mutations in PREX2 that 
help avoid negative regulatory mechanisms (Fine et al., 2009). This hypothesis can be 
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tested by repeating these colony formation experiments to compare R297C to wild type 
PREX2, and then observing whether R297C increases the number of colonies formed 
when co-expressed with PI3K mutants. We also found that R297C showed significantly 
reduced PI(3,4,5)P3 binding compared to wild type PREX2, which could explain why 
this mutant was particularly insensitive to PI3K dependent phosphorylation. Importantly, 
R297C was still present on the membrane, suggesting that it does not require strong 
PI(3,4,5)P3 binding to translocate to the membrane. It is possible that R297C binding to 
Gβγ on the membrane is sufficient for membrane localization. It may also be the case that 
PREX2 has interfaces with the membrane that do not rely on binding to signal dependent 
second messengers.  
In our analysis of the effect of these tumor mutations on PREX2 GEF activity, we 
were surprised to find that the mutants generally had reduced GEF activity. While 
PI(3,4,5)P3 stimulated the GEF activity of all four mutants, the level of PI(3,4,5)P3 
stimulation was reduced compared to wild type PREX2. Interestingly, while R155W and 
R363Q both had reduced Gβγ stimulated GEF activity compared to wild type PREX2, 
activation of both R297C and R299Q by Gβγ was unaffected. It is unclear why these 
tumor mutants generally have lower PI(3,4,5)P3 and/or Gβγ dependent activation. It is 
possible that these mutants, particularly R297C and R299Q, are able to avoid PAK 
mediated negative regulation to create a more prolonged RAC1 activation, but in doing 
so they sacrifice a small amount of GEF activity. In this model, having a longer lasting 
RAC1 activation would be more beneficial to the tumor cell than a higher spike of RAC1 
activity immediately following insulin stimulation that is subsequently turned off by 
PAK. Further work needs to be done to confirm whether the ability of these tumor 
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mutants to avoid PAK phosphorylation is important to create a more oncogenic form of 
PREX2. It is likely that these mutants have diverse mechanisms of promoting 
tumorigenesis, and given the role of PREX2 as an inhibitor of PTEN, some of these 
tumor mutants may be affecting tumorigenesis by altering PTEN function in tumors, a 














































BACKGROUND AND SIGNIFICANCE 
PREX2 is a PTEN interacting protein, and this interaction results in the inhibition 
of PTEN phosphatase activity (Fine et al., 2009). PREX2 inhibition of PTEN appears to 
be particularly important in insulin signaling (Hodakoski et al., 2014). Further 
characterization of PTEN inhibition by PREX2 revealed a complex mechanism. High 
affinity binding between PREX2 and PTEN is mediated by interactions between the IP4P 
domain of PREX2 and the PDZ binding domain on the C-terminus of PTEN; however, 
this interaction does not mediate PTEN inhibition. There is also low affinity binding that 
occurs between the PH domain of PREX2 and the phosphatase and C2 domains of PTEN, 
and it is this interaction that is required for inhibition of PTEN. Additionally, inhibition 
of PTEN by the PREX2 DHPH domain, but not the PH domain alone, requires the PTEN 
C-terminal tail to be phosphorylated. Taken together, the current model for PTEN 
inhibition is that the high affinity interaction mediated by the PREX2 IP4P domain 
initiates binding, which allows the PREX2 DHPH domain to sense the phosphorylation 
state of PTEN. Phosphorylated PTEN then causes conformational changes in the PREX2 
DHPH domain, allowing the PH domain to inhibit PTEN (Figure 1.2) (Hodakoski et al., 
2014). This is the first time that a PH domain has been shown to regulate PTEN, and in 
this chapter we sought to further characterize the binding region within the PREX2 PH 
domain. Further, we hypothesized that PTEN and RAC1 are not the only insulin related 
proteins that interact with PREX2. This hypothesis is supported by a previous study 
showing that PREX2 can interact with mTOR (Hernandez-Negrete et al., 2007). Herein, 
we identified additional interactors that may be important for the role of PREX2 within 




The β3β4 loop region of the PREX2 PH domain is responsible for PTEN binding 
The structure of multiple PH domains has been solved, and these studies have 
revealed that PH domains share a high level of structural homology despite having low 
levels of homology among their sequences. PH domains consist of seven β strands that 
form two beta sheets that closely pack on top of one another, forming a sandwich like 
structure. The C-terminal portion of the PH domain contains an α-helix that closes one 
end of the sandwich. The variable loops that connect the β1β2, β3β4, and β6β7  strands 
protrude from the end of the PH domain opposite the helix, and the sequences and length 
of these loops can differ greatly between PH domains (Rebecchi and Scarlata, 1998). 
These loops are also often the site of lipid or ligand binding. In Chapter 2 we 
characterized PREX2 binding to PI(3,4,5)P3 and found that residues surrounding the β1β2 
loop were critical for this interaction. Further, the β3β4 loop of the PREX2 PH domain 





Figure 5.1 – The N-terminal half of the PREX2 PH domain confers binding 
to PTEN A) Sequence of PREX2 PH domain with potential secondary structures 
indicated from model. B) Western blot analysis of GST PTEN pull downs of in 
vitro translated PREX2 PH domain fragments. 
A
Assigned Secondary PREX2 PH domain Structure
EEEEEEEEEEECCCCCEEEEEEEEEEEEEEEECCCCCCCCCCCCCCCCEEEEEEEE
EMLMCGVLLKI SSGNIQERVFFLFDNLLVYCK RKHRRLKNSKASTDGH RYLFRGRI
CCCEEEEEEECCCCECCCCCCCCECEEEEEEECCCCEEEEEEECCHHHHHHHHHHHHHHHH
NTEVMEVENVDDGTADFHSSGHIVVNGWKIHNTAKNKWFVCMAKTPEEKHEWFEAILKERE
C - random coil
H - helix






























































These conserved structures make it possible to predict secondary structures of PH 
domains when a crystal structure is not available. As shown in Figure 2.10, we made a 
model of the PREX2 PH domain, and the potential residues that comprise the β1β2  loop 
and β3β4 loop were identified (Figure 5.1A).  To determine if these variable loops were 
important for PREX2 binding to PTEN, two fragments of the PH domain were generated. 




Figure 5.2 – The β3β4 loop of the PREX2 PH domain is required for binding 
to PTEN A) PREX2 PH domain fragments were generated to identify important 
regions for PTEN binding B) Western blot analysis of GST PTEN pull downs of 
in vitro translated PREX2 PH domain fragments. C) Western blot analysis of GST 














































































































































































loops, while the second fragment was comprised of residues 301-361. Using a rabbit 
reticulocyte lysate in vitro translation system, these PH domain fragments were made and 
their ability to bind to GST PTEN was assessed (Figure 5.1B). The 245-300 fragment 
bound to GST PTEN at a comparable level to that of the full length PH domain, while the 
301-361 fragment did not bind at all. This suggests that the β1β2 and β3β4 loops are 
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Figure 5.3 – Summary of PTEN, RAC1, and PI(3,4,5)P3 
binding to the variable loops of PREX2 PH domain The 
PREX2 PH domain fragments tested are shown and their ability to 
bind to GST PTEN is indicated at left by either a green check 
mark to indicate it can bind to PTEN, or a red cross to indicate 
that it cannot bind to PTEN. The red box surrounds the minimal 
binding region identified by these fragments. Regions that interact 
with PI(3,4,5)P3 and RAC1 are also indicated. 
involved in PTEN binding. The 245-300 fragment was then broken down to separate the 
two putative variable loop structures that it contained (Figure 5.2A). The 264-300 
fragment that eliminated the putative β1β2 loop retained PTEN binding ability, while the 
245-279 fragment that removed the β3β4 loop did not bind (Figure 5.2B). Further, the 
245-281 fragment, which added just two arginine residues to the non-binding fragment, 
recovered a small amount of PTEN binding, while the 245-292 fragment, which adds 
back most of the β3β4 loop, bound even better (Figure 5.2B). This suggests that the β3β4 
loop is the region that is important for PTEN binding. As previously mentioned, the β3β4 
loop was also reported to be the region of the PH domain that is required for PREX2 
targeting of RAC1 (Joseph and Norris, 2005). We tested binding of these same PREX2 
fragments in Figure 5.2A to GST RAC1, and observed a very similar binding pattern as 
we did for GST 
PTEN (Figure 
5.2C). This is 
consistent with 
the other study 
by Joseph et al. 
and suggests that 
both PTEN and 
RAC1 are 
binding to the 





Figure 5.4 – PREX2 binds critical proteins in insulin signaling pathway A and B) 
Western blot analysis of V5 PREX2 immunoprecipitations.   
 
domain. The binding pattern of these PREX2 PH domain fragments to GST PTEN are 
summarized in Figure 5.3 and the putative regions of PTEN, RAC1, and PI(3,4,5)P3 
binding are indicated.   
PREX2 co-immunoprecipitates with critical proteins in the insulin signaling pathway 
 In addition to characterizing the binding of PREX2 to PTEN, RAC1, and 
PI(3,4,5)P3, we investigated the binding of PREX2 to other proteins involved in the 
insulin signaling pathway. Interestingly, we consistently noticed that a 150kDa protein 
that was tyrosine phosphorylated after insulin treatment co-imunoprecipitated with V5 
PREX2 (Figure 5.4A). This is close in size to the IRS family of proteins, so the 
possibility of a PREX2-IRS interaction was investigated. In HEK293 cells, IRS4 is the 
primary isoform, so we probed for this protein in PREX2 immunoprecipitations (Fantin 
et al., 1998; Lavan et al., 1997). Using an antibody specific to IRS4, we found that IRS4 
co-immunoprecipitated with V5 PREX2. In addition, the regulatory subunit of PI3K, p85, 
and the phosphorylated version of insulin receptor, was also present in V5 PREX2 




Figure 5.5 – Interactions with insulin receptor and 
p85 occur primarily through DHPH domain of 
PREX2 Western blot analysis of V5 
immunoprecipitations from HEK293 cells expressing 




Insulin          -           -           +             -          +
DHPH ΔDHPH
V5 IP
affected by insulin stimulation. Further, p85 bound to the PREX2 DHPH domain but was 
unable to bind to a fragment of PREX2 containing everything except the DHPH domain, 
called ΔDHPH (Figure 5.5). 
Phosphorylated insulin 
receptor bound both DHPH 
and ΔDHPH, however it 
showed a significant 
preference for DHPH. The 
fact that these interactions 
with critical insulin related 
proteins occurs through the 
DHPH domain of PREX2 is 
an interesting result given that PTEN, RAC1, and PI(3,4,5)P3 all have binding sites in 
this region as well.  
 
DISCUSSION 
 As discussed in the introduction, PREX2 has a significant role in insulin 
signaling, both in cancer cell lines and in mice. Here, we analyzed PREX2 interactions 
with other proteins in the insulin-signaling pathway.  We first focused on PREX2 binding 
to the PI(3,4,5)P3 lipid phosphatase PTEN, particularly the binding mediated by the 
PREX2 PH domain. While it is not the primary region responsible for PTEN binding, the 
PH domain is responsible for PTEN inhibition (Hodakoski et al., 2014). By analyzing a 
series of truncation mutants of the PREX2 PH domain, we discovered that the β3β4 loop 
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was required for PTEN binding. Given that the PH domain alone can inhibit PTEN both 
in vitro and in cells, it will be important to establish whether the β3β4 loop is also the 
minimal region required for inhibition. These small fragments of the PH domain are 
difficult to express in cells, so this type of analysis may require deletion mutants in the 
full length PH domain or in the full length protein. Additionally, it may be useful to 
perform mutational analysis on residues within the β3β4 loop to identify the specific 
residues that are required for PTEN binding or inhibition. This type of analysis could 
yield a full length PREX2 mutant that is unable to inhibit PTEN, but retains other PREX2 
functions. Ideally this mutant would still be able to act as a RAC GEF, which would 
allow us to separate the roles of PTEN inhibition from RAC activation in different 
PREX2 outputs, such as glucose uptake. However, this may be difficult given that this 
region of the PH domain is also important for binding to RAC, and mutations that block 
PTEN inhibition may also affect GEF activity. If it is possible to make this type of 
mutant that is specifically deficient in PTEN inhibition, CRISPR technology could then 
be used to knock this mutant into cell lines and study the importance of PTEN inhibition. 
Further, this mutant could be knocked into a mouse to study the importance of PTEN 
inhibition in vivo. 
Further characterization of the specific residues responsible for PREX2 PH 
domain mediated inhibition could also help in designing small molecules that modulate 
PTEN function. By knowing the specific interactions that are required for inhibition, it 
may be easier to rationally select types of molecules that could prevent PREX2 inhibition 
of PTEN and activate PTEN. Given the role of PTEN as a tumor suppressor, activating 
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PTEN phosphatase activity with a drug would have great potential as a cancer 
therapeutic.  
 PREX2 PH domain mediated inhibition of PTEN is also exciting given the fact 
that many proteins in the human proteome contain PH domains, and it presents the 
possibility that PH domain binding and inhibition may be a more universal mechanism of 
PTEN regulation. Given that PI(3,4,5)P3 is the primary substrate for PTEN, and that 
PI(3,4,5)P3 binds to PH domains, PTEN will often be in close proximity to PH domain 
containing proteins within the cell, making this a feasible possibility. If PTEN regulation 
by PH domains is common to PH domains other than PREX2, this would have an 
enormous impact on cancer biology given the role of PTEN as a tumor suppressor, and 
would more generally impact cellular biology given the wide range of important cellular 
functions that PTEN can influence. Our model of the PREX2 PH domain shows that the 
β3β4 loop is very long and flexible compared to β3β4 loops of other PH domains. In order 
to find other candidate PH domains that could also bind and inhibit PTEN, it may be 
important to identify those that have long and flexible loops like PREX2. Interestingly, 
we also generated a model of the PREX1 PH domain, which suggested that PREX1 also 
has a long and flexible β3β4 loop; however, full length PREX1 does not bind to PTEN 
(Hodakoski et al., 2014). This suggests that PH domain mediated inhibition of PTEN 
could be specific for PREX2. This may be especially more likely given the complexity of 
PREX2 mediated inhibition of PTEN. Even though the PH domain is required to inhibit 
PTEN, the PREX2-PTEN interaction is mediated primarily through the IP4P domain of 
PREX2. Given this model, it may be important to identify the precise region within the 
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IP4P domain of PREX2 that binds PTEN, and then look for candidates that have 
homology both to this region, and to the β3β4 loop region of the PREX2 PH domain.  
 In this chapter, we also established that PREX2 interacts with other insulin related 
proteins in addition to PTEN and RAC1. It has already been reported that PREX2 can 
bind to the phosphorylated insulin receptor, but not the EGF receptor (Hodakoski et al., 
2014). Here, we show that p85 and IRS4 also co-immunoprecipitate with V5 PREX2. 
The functional consequences of these interactions are currently unclear; however it is 
possible that these interactions could play a role in the observed effect of PREX2 loss on 
insulin signaling in the mouse. PREX2 could serve as a scaffold near the insulin receptor, 
helping to stabilize complexes involving the receptor and these important signaling 
molecules that interact with PREX2, such as IRS proteins, p85, PTEN, and RAC1. From 
our data, it is not possible to determine whether these interactions are direct or whether 
PREX2 is indirectly interacting with these proteins as part of large signaling complex. 
Further experiments testing in vitro binding of purified proteins could be useful in 
determining whether these proteins are direct binding partners of PREX2. Interestingly, a 
complex including both RAC1 and p85 has been previously identified. This complex 
involves the GEF SOS1, and appears important for RAC1 function in MEFs (Innocenti et 
al., 2003). This suggests that the PREX2 interactions we have identified here may also 






























The studies outlined in this thesis have characterized novel PREX2 
phosphorylation events and protein interactions. PREX2 is a protein with established 
roles in important signaling pathways, such is insulin signaling, and its functions as a 
RAC1 GEF and PTEN inhibitor give PREX2 the potential to affect many cellular 
processes. Further, PREX2 is commonly altered in cancer and PREX2 mutants have been 
shown to promote tumorigenesis. Thus, it is critical to understand how PREX2 is 
regulated to not only gain a greater understanding of intracellular signaling but to 
potentially modulate PREX2, RAC1, or PTEN function in disease states where they are 
altered.  
In Chapter 2, we showed that PREX2 was phosphorylated during insulin 
stimulation. We also identified S1107 as an insulin-stimulated phosphorylation site on 
PREX2. We found that phosphorylation of PREX2 depended on PI3K and required 
PREX2 binding to PI(3,4,5)P3, but was not regulated by the well characterized 
PI(3,4,5)P3 dependent kinases AKT, PDK1, and mTORC1. Through these analyses, we 
also demonstrated that the β1β2 loop region of the PREX2 PH domain was essential for 
binding to PI(3,4,5)P3. Importantly, PREX2 was also phosphorylated after expression of 
Gβγ, suggesting that phosphorylation was associated with PREX2 activation. Further, the 
protein phosphatase PP1α dephosphorylated both the insulin and Gβγ dependent 
phosphorylation events on PREX2, while PP2A reduced insulin-induced phosphorylation 
of PREX2.  
In Chapter 3, we pursued the consequences of phosphorylation for PREX2 
function, and used this information to identify a PREX2 kinase. We found that 
phosphorylation reduced PI(3,4,5)P3 and Gβγ stimulation of PREX2 GEF activity 
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towards RAC1, and that this is likely due to phosphorylated PREX2 having a much lower 
affinity for the membrane, PI(3,4,5)P3, and Gβγ.  This was an interesting finding given 
the data in Chapter 2 showing that PREX2 phosphorylation depended on PI(3,4,5)P3 and 
Gβγ, the two second messengers known to activate its GEF activity. Taken together, 
these two findings suggested that phosphorylation was part of a negative feedback circuit 
to reduce PREX2 GEF activity after it had been stimulated by a signal. Consistent with 
negative feedback, RAC1 also induced PREX2 phosphorylation. This led to the 
discovery that PREX2 was phosphorylated and negatively regulated by the RAC1 
dependent PAK family of kinases. Phosphorylation at S1107 was also regulated by PAK, 
suggesting that it may be a PAK phosphorylation site. Altogether, PAK phosphorylation 
of PREX2 allows for tight regulation of the length and amplitude of RAC1 activation, 
resulting in a transient RAC1 signal following ligand binding. 
 Our data showing that PREX2 function is tightly regulated by insulin-induced 
phosphorylation further supports a critical role for PREX2 in the insulin signaling 
pathway. Future experiments should focus on the effect of this feedback circuit on 
downstream insulin signaling. Given the major deficiencies in glucose uptake in   
PREX2-/- mice, and the importance of RAC1 in glucose uptake and GLUT4 trafficking, 
glucose uptake is a particular insulin dependent physiological process where this 
feedback loop should be studied. Glucose uptake occurs primarily in the muscle tissue, 
and also occurs to a lesser extent in the adipose tissue (Leto and Saltiel, 2012). Given this 
fact, it is surprising that the two published reports characterizing PREX2-/- mice show 
very low levels of PREX2 in the muscle (Donald et al., 2008; Hodakoski et al., 2014). 
Interestingly, mRNA levels of PREX2 are highest in the skeletal muscle, and PREX2 was 
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originally cloned from muscle tissue (Donald et al., 2004; Rosenfeldt et al., 2004). It is 
possible that there is an issue with detection of PREX2 in the muscle, potentially because 
of difficulties extracting it from this tissue or because of post-translational modifications 
that prevent detection. If PREX2 levels are actually very low in the muscle, then a small 
amount of protein may be enough to elicit an effect, or the knockout of PREX2 from 
adipose tissue is sufficient for the phenotypes that are seen. The presence of PREX2 in 
the muscle should be investigated in more detail before further studies are done to probe 
the role of PREX2 in the skeletal muscle, and the role of PAK1 mediated negative 
feedback. Once this is established, model systems of muscle and adipocytes that are set 
up to robustly measure glucose uptake and GLUT4 membrane translocation can be 
studied. For example, differentiated L6 rat myotubes or differentiated mouse 3T3-L1 
adipocytes that stably express a tagged version of GLUT4 are often used as models to 
study glucose metabolism in culture. The effect of PREX2 on these processes can be 
studied through overexpression or knockdown of PREX2 in these systems. Further, by 
using the S1107E mutant, we can potentially determine whether PREX2 phosphorylation 
is important for these processes. Additionally, CRISPR technology could be used to 
knock-in phospho-mimicking or non-phosphorylatable mutants in these cell lines to study 
the effect of phosphorylation in the more physiologically relevant endogenous setting. 
While we were able to show that these PAK dependent phosphorylation events 
were induced by Gβγ  overexpression, future studies should try to identify specific GPCR 
mediated signals that activate this signaling pathway. Sphingosine-1-phosphate and 
fMLP are two potential candidates given that PREX2b and PREX1, respectively, have 
reported roles downstream of these GPCR ligands.  Fatty acids also bind and activate 
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GPCRs. Two of these fatty acid-activated GPCRs, GPR41 and GPR120, increase glucose 
uptake in mouse adipose and muscle cells.  This is particularly interesting given the role 
of PREX2 in glucose uptake. The short chain fatty acids propionate and valerate both 
increased glucose uptake through GPR41, while the long chain fatty acid 
docosahexaenoic acid and the agonist compound A (cpdA) increased glucose uptake 
through GPR120 (Han et al., 2014; Oh da et al., 2014; Oh et al., 2010). It is possible that 
these molecules, or any other fatty acids, activate PREX2 GEF activity, and therefore 
increase PAK phosphorylation of PREX2. In this case, chronically high levels of fatty 
acids could lead to hyperactivation of PAK1 mediated negative regulation of PREX2. 
This would presumably lead to inefficient insulin signaling and promote insulin 
resistance.  
 In order to most effectively study the effect of PAK phosphorylation in vivo, 
including the effect on glucose metabolism, it will likely be important to identify any 
additional PAK phosphorylation sites on PREX2 that may exist. Our data suggests that 
S1107 is not the only site regulated by insulin or PAK, and the identification of more 
PAK dependent phosphorylation sites may allow for the generation of a non-
phosphorylatable mutant or a more physiologically potent phospho-mimicking mutant 
that has significant signaling and functional phenotypes. Our mass spectrometry revealed 
that in addition to S1107, the region around this residue was heavily phosphorylated, 
providing more candidate residues for future study.  
Furthermore, now that we have a greater understanding of PREX2 
phosphorylation, it will likely be easier to identify more relevant phosphorylation sites 
using mass spectrometry. In our mass spectrometry analysis, we compared PREX2 that 
106 
   
was purified from HEK293 cells that were either starved and treated with a PI3K 
inhibitor or treated with insulin. We also included a condition where insulin was 
combined with calyculin A treatment, which produces a very highly phosphorylated 
species of PREX2. We did indeed find many more residues that were phosphorylated 
after calyculin A treatment; however, calyculin A may increase phosphorylation at sites 
that are not specific to PAK kinases. Gβγ, RAC1, and PAK1 overexpression all strongly 
induce phosphorylation and would potentially be much more useful contexts to discover 
PAK phosphorylation sites. In addition, co-overexpression of the dominant negative 
forms of RAC1 and PAK1 result in completely dephosphorylated PREX2. Thus, mass 
spectrometry analysis comparing PREX2 that is dephosphorylated by co-overexpression 
of these dominant negative mutants to PREX2 that is phosphorylated by RAC1 or PAK1 
co-overexpression would be more likely to reveal new sites that are phosphorylated by 
PAK kinases.   
It will also be important to determine whether there is an effect of PAK 
phosphorylation on PREX2 inhibition of PTEN. We know from our data in Figure 3.3B 
that PAK phosphorylation of PREX2 has no effect on binding to GST PTEN. However, 
binding to PTEN does not necessarily correlate with inhibition, especially given the 
current model of inhibition where the high affinity binding between PREX2 and PTEN 
through the C-terminus is not the same interaction that regulates inhibition (Hodakoski et 
al., 2014). Phosphorylation of PREX2 may not affect the C-terminal binding, but could 
result in conformational changes that prevent or enhance the ability of the PH domain to 
access and inhibit the phosphatase domain of PTEN. In vitro inhibition assays with 
phosphorylated or dephosphorylated purified PREX2 and purified PTEN will be critical 
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to answer this question. However, given the data from the PREX2-/- mice and our data 
from this study, we would hypothesize that it is unlikely that PAK phosphorylation of 
PREX2 is affecting PTEN inhibition. In adipose tissue of PREX2-/- mice, there is reduced 
AKT phosphorylation compared to wild type mice as soon as two minutes after insulin 
stimulation, and in PREX2-/- MEFs, the reduction in AKT phosphorylation persists until 
at least the 60 minute time point (Hodakoski et al., 2014). This suggests that PREX2 is 
inhibiting PTEN at both early and later time points after insulin stimulation. Given that 
PAK phosphorylation of PREX2 changes significantly during this time course, and PTEN 
inhibition does not appear to be changing, PAK phosphorylation of PREX2 is likely not 
affecting PTEN inhibition. However, even if PAK has no effect on PTEN inhibition, it is 
certainly still possible that another kinase is mediating additional phosphorylation events 
on PREX2 to regulate inhibition of PTEN. This possibility will be discussed later in this 
chapter in the context of results obtained in Chapter 5. 
In Chapter 4, we began to investigate whether PREX2 phosphorylation is altered 
in cancer. We identified four recurrent PREX2 tumor mutations: R155W, R297C, 
R299Q, and R363Q. We found that all of these mutants had lower levels of insulin and 
PAK1-induced phosphorylation compared to wild type PREX2. The phosphorylation of 
R297C and R299Q was almost completely eliminated. We also characterized the GEF 
activity of these mutants and showed that all four had reduced PI(3,4,5)P3 stimulated 
GEF activity, while only R155W and R363Q had reduced Gβγ stimulated GEF activity. 
In addition, the PREX2 R297C mutant had reduced phosphorylation when co-expressed 
with PI3K activating tumor mutations. This effect might be explained by the ineffective 
binding of R297C to PI(3,4,5)P3. However, despite having reduced PI(3,4,5)P3 binding, 
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R297C could still localize to the membrane and stimulate invasion of BT549 breast 
cancer cells.  
Lastly, in Chapter 5 we looked at PREX2 interactions with other proteins within 
the insulin signaling pathway, with a focus on characterizing the interaction between the 
PREX2 PH domain and PTEN. Using fragments of the PREX2 PH domain, we showed 
that the β3β4 loop of the PREX2 PH domain was required for binding of the PH domain 
to PTEN. We also found that PREX2 could bind to p85, the insulin receptor, and IRS4, 
primarily through the DHPH domain; however, it is unclear whether these interactions 
with PREX2 are direct or what effect they have on insulin signaling or PREX2 function. 
It is possible that there is a complex at the membrane that includes all of these proteins 
and is necessary to propagate the insulin signal. This is a hypothesis that warrants further 
study.  
The discovery that PTEN binds to the β3β4 loop of the PREX2 PH domain is 
interesting given the number of signaling molecules that appear to bind to these variable 
loops. Our data in Chapter 2 established that the nearby β1β2 loop region mediated 
PREX2 binding to PI(3,4,5)P3. Also, as previously mentioned and confirmed by our data, 
the β3β4 loop can bind to RAC1 (Joseph & Norris, 2005). Furthermore, it has also been 
reported that the PH domain is necessary for binding of PREX2b to Gβγ (Li et al., 
2005b). This sets up a model where these variable loops within the PREX2 PH domain 
are potentially coordinating interactions with at least four molecules that are critical for 
its function within the cell: PTEN, RAC1, Gβγ, and PI(3,4,5)P3. Future studies should 
focus on how these interactions are coordinated. For example, can PREX2 and RAC1 
bind to the β3β4 loop at the same time? If not, it will be very interesting to explore the 
109 
   
possibility that competitive binding for the same location could be responsible controlling 
whether PREX2 is acting as a GEF for RAC1, or an inhibitor of PTEN. It could also be 
true that PTEN and RAC1 are able to promote binding of the other to the PREX2 PH 
domain, meaning that PREX2 would be a better inhibitor of PTEN in the same context 
where it is an active GEF. The effect of PI(3,4,5)P3 binding to the nearby β1β2 loop or 
Gβγ  binding to the PH domain could also be influencing the binding of PTEN or RAC1 
to the β3β4 loop, which is another hypothesis that should be addressed in the future.  
The findings in Chapter 5 are also potentially important when combined with the 
mass spectrometry analysis in Chapter 2. Two phosphorylation events in the PTEN-
binding β3β4 loop of the PREX2 PH domain were identified, S288 and T289. If these are 
legitimate phosphorylation events on PREX2, given their location in this critical region 
of the PH domain, it will be very interesting to see if they regulate PREX2 mediated 
inhibition of PTEN. The homologous site to S288 on PREX1, S319, was reported to have 
higher levels of phosphorylation in starved cells, and reduced levels of phosphorylation 
after neuregulin treatment (Montero et al., 2011). In our study, S288 of PREX2 was only 
phosphorylated in the starved and GDC0941 treated sample, which is consistent with the 
PREX1 data (Figure 2.4B). Interestingly, T289 had the opposite pattern and was only 
phosphorylated in the insulin and calyculin A treated sample of our mass spectrometry 
analysis. One potential hypothesis is that in starved cells, S288 is phosphorylated and 
T289 is dephosphorylated, and this specific combination prevents PTEN binding to the 
PH domain of PREX2, activating PTEN phosphatase activity to keep PI(3,4,5)P3 levels 
low (Figure 6.1). In this model, immediately upon growth factor stimulation a kinase 




Figure 6.1 – Model for coordination of PREX2 GEF 
activity and PTEN inhibition after receptor tyrosine 
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stimulation would allow PREX2 to bind and activate RAC1. At later time points, PAK 
phosphorylates PREX2 to reduce RAC1 activation, and as the data from the PREX2-/- 
mice would suggest, PREX2 is likely still inhibiting PTEN.     
 Taken together, the findings from Chapters 4 and 5 have interesting implications 
for the role of PREX2 in cancer. One of most commonly mutated residues on PREX2 
was at R297C, which also had one of the most striking biochemical phenotypes. We also 
characterized a recurrent tumor mutation, R299Q, which is in the same area of the PH 
domain as R297C. Both of these mutations are very close to the β3β4 loop of our model 
for the PREX2 PH domain, suggesting that they could potentially alter the ability of 
PREX2 to inhibit PTEN. Both of these residues are positively charged arginine residues, 
and mutating them would change the ionic properties of the area surrounding this 
variable loop, potentially altering its structure. If these mutations in this critical area led 
to an enhancement in PTEN inhibition, it could potentially explain why they were 
selected in cancer. Given that we did not see increases in GEF activity for these mutants, 
it would not be surprising if these mutants were affecting PTEN inhibition. This can be 
tested with purified protein in in vitro PTEN inhibition assays or in cells studying 
phosphorylation of AKT as a readout. If this hypothesis were true, one would expect 
these mutants to only be tumorigenic when PTEN is present. This could be tested by 
performing colony formation assays in cancer cell lines with or without PTEN.  Further, 
in order to analyze these mutants in the endogenous setting and not in the context of 
overexpression, CRISPR can be used to knock-in these mutations into certain cell lines. 
These knock-in cell lines can then be used to look for differences in tumorigenicity, 





Plasmids and constructs: Full length PREX2 was cloned into the pcDNA3.1 V5/His 
vector (Life Technologies) and GST PTEN was cloned into the pGEX4T-1 vector 
(Amersham Bioscience) as previously described (Fine et al., 2009). PTEN G129E was 
made by mutating PCEP4-PTEN, and PREX2 point mutations were made by mutating 
the full length V5/His PREX2 pcDNA3.1 backbone using the QuikChange II XL site 
directed mutagenesis kit (Agilent). PH domain fragments of PREX2 were PCR amplified 
from the V5/His PREX2 pcDNA3.1 backbone, and then they were cloned into the 
pcDNA3.1 V5/His vector using the TOPO-TA cloning kit (Life Technologies). PP1α was 
amplified from cDNA of HEK293 cells, and cloned into the pcDNA3.1 V5/His vector 
using the TOPO-TA cloning kit. p110α mutants were cloned into the pcDNA3.1 vector. 
MYC-pCMV6M- PAK1 WT, PAK1 K299R, and PAK1 T423E were gifts from Jonathan 
Chernoff (Addgene plasmid #12210) (Sells et al., 1997). The HA PAK4 vector was a gift 
of Audrey Minden. The catalytic subunit of PP2A (pcDNA-PP2A/C-HA) was a gift of 
Gen Sheng Wu (Xu et al., 2013). PGEX encoding GST-tagged RAC1 was a gift of Katrin 
Rittinger. The FLAG-Gβ1/HA-Gγ2 vector in the pVITRO2-mcs(Hygro) backbone was a 
gift of Jonathan Backer. MYC RAC1-WT and MYC RAC1-T17N were gifts from Gary 
Bokoch (Addgene plasmids #12985, 12984).  
Antibodies: Mouse V5 primary antibody (R960-25) was purchased from Life 
Technologies. Mouse M2 FLAG (F1804), vinculin (V9131), and actin (A5316) 
antibodies, in addition to mouse anti-V5 agarose affinity (A7345) and anti-M2-FLAG 
agarose affinity (A2220) gels were purchased from Sigma Aldrich. Mouse tubulin 
(MMS-410P) was purchased from Covance. Rabbit PTEN clone 138G6 (9559), total 
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AKT (9272), p308AKT (4056), p473AKT (9271), total ribosomal S6 (2271), p235/236 
S6 (2211), ERK1/2 (9102), p202/204 ERK1/2 (4376), total EGFR (4267), and phospho-
IGF1Rβ (Tyr1135/1136)/IRβ (Tyr1150/1151) (3024) primary antibodies were purchased 
from Cell Signaling Technologies. The rabbit polyclonal pS1107-PREX2 antibody to 
amino acids 1098-1116 (GHDTISNRDpSYSDCNSNRN) was made in collaboration with 
Cell Signaling Technologies. Mouse RAC1 (05-389), p338 RAF1 (05-538), p85 N-SH2 
clone UB93-3 (05-217), p-tyrosine clone 4G10 (05-321) and rabbit IRS4 (06-771) 
primary antibodies were purchased from Millipore. Mouse MYC clone 9E10 (sc-40) 
primary antibody was purchased from Santa Cruz Biotechnology. The PREX2 rabbit 
polyclonal antibody was made by Zymed Laboratories. Secondary antibodies directed 
against rabbit, mouse, and rat IgG conjugated to HRP were purchased from Pierce. 
Cell lines and Transfection: HEK293 and U87MG cells were cultured in DMEM 
(Cellgro) supplemented with 10% (vol/vol) fetal bovine serum (FBS), 100 IU penicillin, 
and 100 μg/mL streptomycin (Cellgro). DBTRG-05MG and BT549 cells were cultured in 
RPMI supplemented with 10% (vol/vol) FBS, 100 IU penicillin, and 100 μg/mL 
streptomycin. When indicated, cells were starved for 16 hours in the appropriate media 
without FBS before treatment. Transfections were performed with Lipofectamine 2000 
(Life Technologies) following the manufacturer’s protocol. Unless otherwise indicated, 
insulin treatments were for 30 minutes at 5 μg/mL. For treatment with a small molecule 
inhibitor, the indicated concentrations were incubated with the cells for 15 minutes prior 
to addition of insulin, or for 30 minutes prior to harvesting if no insulin was added.  
GST fusion protein purification: Plasmids were transformed in to BL21(DE3) pLysE 
chemically competent cells (Invitrogen). Single colonies were picked and grown in a 
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small culture overnight, and this was used to inoculate a 500mL culture of LB broth until 
the OD600 was 0.3-0.5 when protein expression was induced by the addition of 0.1mM 
Isopropyl β-D-1-thiogalactopyranoside (Sigma) for 16 hours at 23°C. The bacterial pellet 
was resuspended in 10mL of lysis buffer (50 mM TRIS pH 7.2, 400 mM NaCl, 1% 
Triton X-100, 1 mM EDTA). The lysate was sonicated, and then centrifuged for 1 hour at 
40,000 x g. The supernatant was incubated overnight with glutathione sepharose beads 
rotating at 4°C (GE Healthcare Life Sciences). Beads were then washed 3 times in lysis 
buffer followed by 3 times in a buffer containing 25 mM TRIS pH 7.5 and 150 mM 
NaCl. The beads were then stored and frozen in this same buffer. To elute, the beads 
were incubated with the bead bed volume of elution buffer (25 mM TRIS pH 8.0, 150 
mM NaCl, 50 mM glutathione) for 30 minutes shaking at room temperature. The beads 
were removed, and eluted proteins were aliquoted and snap frozen. To quantify both 
eluted and bead bound proteins, samples were diluted in 2X Laemmli sample buffer (125 
mM TRIS pH 6.8, 4% SDS, 20% glycerol, 10% beta-mercaptoethanol, 0.05% 
bromophenol-blue) and then were run on a gel with BSA standards and quantified using 
Gel Code Blue (Pierce).  
In vitro Lambda phosphatase assay: For endogenous PREX2, HEK293 cells were 
harvested in lysis buffer (20 mM HEPES pH 7.4, 0.25% NP-40, 150 mM NaCl, 1 mM 
EDTA, 1 mM NaOV3, 1 mM NaF, 100 nM calyculin A, 1x eukaryotic protease inhibitor 
cocktail (Sigma)). The lysates were vortexed, sonicated, centrifuged at 4°C for 30 
minutes, and then combined with 5 μL PREX2 antibody and 20 μL of Protein A/G Plus 
agarose beads (Santa Cruz), rotating at 4°C for 4 hours. The beads were then washed 5 
times in lysis buffer. For analysis of exogenous PREX2, HEK293 cells expressing V5 
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PREX2 were harvested in lysis buffer (25 mM TRIS pH 7.5, 0.2% Triton X-100, 200 
mM KCl, 10% glycerol, 1 mM EDTA, 1 mM EGTA, 1 mM NaOV3, 1 mM NaF, 100 nM 
calyculin A, 1x eukaryotic protease inhibitor cocktail). Lysates were vortexed, sonicated, 
centrifuged at 4°C for 30 minutes, and then incubated with V5 agarose beads (Sigma) for 
4 hours rotating at 4°C. Beads were then washed 5 times in lysis buffer. For both V5 
PREX2 and endogenous PREX2, the phosphatase reactions were set up in 100 μL using 1 
μL of Lambda phosphatase from New England Biolabs along with the supplied 10x 
Lambda phosphatase buffer and 10x MnCl diluted in water. Reactions were incubated at 
30°C for 20 minutes and were terminated with 2x Laemmli sample buffer.  
Mass Spectrometry: V5 PREX2 was expressed in HEK293 cells. Cells were starved and 
then treated with either 500 nM GDC-0941 (referred to as the unstimulated state), 5 
μg/ml insulin, or insulin and 100 nM calyculin A (both of these conditions are referred to 
as the stimulated state). Cells were lysed in buffer containing 25 mM TRIS pH 7.5, 0.2% 
Triton X-100, 200 mM KCl, 10% glycerol, 1 mM EDTA, 1 mM EGTA, 1 mM NaOV3, 1 
mM NaF, 100 nM calyculin A, and 1x eukaryotic protease inhibitor cocktail. The lysate 
was vortexed, sonicated, and centrifuged at 4°C for 30 minutes, and then pre-cleared with 
Protein A/G PLUS-agarose beads and mouse IgG (Santa Cruz). The beads were removed, 
and V5 PREX2 was isolated on V5 agarose beads by incubating them with the lysate for 
4 hours rotating at 4°C. Beads were washed 5 times in lysis buffer, and resuspended in 2x 
Laemmli sample buffer. For each condition, two samples of approximately 3 micrograms 
of V5 PREX2 were run by SDS-PAGE and the bands were excised. Bands were digested 
overnight with sequencing grade trypsin and chymotrypsin (Promega). These digests 
were analyzed separately and phosphopeptides were enriched using titanium dioxide spin 
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tips (Protea) followed by microcapillary liquid chromatography / tandem mass 
spectrometry (LC-MS/MS). Enriched peptides were introduced to the Orbitrap Elite mass 
spectrometer (Thermo Fisher Scientific) in positive ion CID mode using a data-dependent 
acquisition (DDA) with an EASY-NLC II nanoflow HPLC (Proxeon) (75 mm ID x 15 
cm C18 column) at 300 nL/min. MS/MS spectra were searched against the reversed and 
concatenated SwissProt (Version 2012_3, Uniprot) protein database and the Prex2V5His 
custom database using Mascot server 2.4 and data were analyzed using Scaffold 4 
software. Peptides were reported with a false discovery rate (FDR) threshold of 1%. 
PREX2 siRNA: DBTRG cells in 6 well plates were transfected with 100 pmol of either 
control or PREX2 siRNA (5’ CCCUGGACAGUGCAUUAUCAAUU, antisense – 5’ 
UUGAUAAUGCACUGUCCAGGGUU)(Sigma). 48 hours later cells were treated as 
indicated, and harvested in 2X Laemmli sample buffer. 
In vitro PI3K kinase assay (PREX2 as a substrate): Either V5 PREX2 or empty vector 
was expressed in HEK293 cells. Cells were starved and then lysed in buffer containing 
25 mM TRIS pH 7.5, 0.2% Triton X-100, 200 mM KCl, 10% glycerol, 1 mM EDTA, 1 
mM EGTA, 1 mM NaOV3, 1 mM NaF, 100 nM calyculin A, and 1x eukaryotic protease 
inhibitor cocktail. The lysate was vortexed, sonicated, and centrifuged at 4°C for 30 
minutes, and then pre-cleared with Protein A/G PLUS-agarose beads and mouse IgG. The 
beads were removed, and V5 PREX2 was isolated on V5 agarose beads by incubating 
them with the lysate overnight rotating at 4°C. Beads were washed 2 times in lysis buffer, 
followed by 5 times in wash buffer containing 20 mM TRIS pH 7.4, 100 mM NaCl, 0.5 
mM EDTA. After last wash, beads were resuspended in 70 μL of the wash buffer. 20 μL 
of 30 mM HEPES/1 mM EGTA solution was added to beads (this is buffer used for lipids 
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when the lipid is the substrate, but PREX2 is the substrate, so just added the buffer). 1 μL 
of 0.1 μg/ μL PIK3CA/PIK3R1 (Invitrogen) and 1 μL of 100 μM GDC0941 (1 μM final 
concentration) or 1 μL of DMSO was added to the reaction followed by 10 μL of the 
ATP mix. The ATP mix consisted of 5.5 μL 100 mM HEPES pH 7, 2 μL 500 mM 
MgCl2, 0.5 μL 10 mM cold ATP, and 2 μL of 10 μCi/μL ATP (γ-
32P). The reactions were 
left at room temperature for 10 minutes, followed by 10 minutes at 37°C. Beads were 
then washed 2 times in wash buffer, and resuspended in 2x Laemmli sample buffer. 
Incorporation of [γ-32P]-ATP was detected by gel electrophoresis. 
In vitro PI3K kinase assay (lipid substrate): The silica gel thin layer chromatography 
(TLC) plate was activated by immersing in 1% potassium oxalate in 3:2 methanol:water 
solution for 5 minutes. Plate was then baked in 100°C oven for 1 hour. After removal 
from oven the plate was allowed to reach room temperature. Lipid mixture was then 
made by adding 4 μg phosphatidylinositol and 12 μg phosphotidylserine (both in 10 
μg/μL chloroform solutions from Avanti) per sample to a tube. Lipid mixture was dried 
under gentle flow of nitrogen gas, and then lipids were dissolved in 20 μL/reaction of 30 
mM HEPES/1 mM EGTA solution. Solution was vortexed, and then sonicated 
(periodically putting on ice if using a probe sonicator) until solution was no longer 
cloudy, and then left at room temperature. The reaction was then set up as follows: 70 μL 
of 20 mM TRIS pH 7.4, 100 mM NaCl, 0.5 mM EDTA, 20 μL of lipid mix, 1 μL of 0.1 
μg/μL PIK3CA/PIK3R1, 1 μL of 100 μM GDC0941 (1 μM final concentration) or 1 μL 
of DMSO, and then 10 μL of ATP mix (added last). ATP mix consisted of 5.5 μL 100 
mM HEPES pH 7, 2μL 500mM MgCl2, 0.5uL 10mM cold ATP, and 2μL of 10 μCi/μL 
ATP [γ-32P]. Reaction was incubated for 10 minutes at room temperature and stopped by 
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adding 25 μL of 5N HCl. Then 160 μL of 1:1 chloroform:methanol was added to each 
reaction, solution was vortexed for 30 seconds, and then centrifuged for 2 minutes to 
separate aqueous and organic layers. 50 μL of the organic layer (bottom) was removed 
and added dropwise to the silica plate, and the spot was then dried. TLC chamber was set 
up by wetting a piece of filter paper within the chamber with mobile phase (65:35 n-
propanol:acetic acid). Plate was put on the stand in the chamber and enough mobile phase 
was added to the chamber to cover the bottom of the plate, but remain lower than the 
spots of loaded sample. Mobile phase was allowed to run overnight, and the next morning 
the plate was exposed to the phosphorimager for 1 hour and scanned on a Typhoon Trio 
scanner (GE Healthcare Life Sciences). 
Modeling of PREX2 PH domain: For modeling we used the software Modeller version 
9v9 maintained by the Sali laboratory (Webb and Sali, 2014). The template for the PH 
domain of PREX2 was the crystal structure of the PH domain of CDC42 (PDB entry 
2DFK, chain A). To explore the variations in query-template alignments, we used S4, a 
program that relies on information on secondary structure elements of the template 
(Kuziemko et al., 2011). The alternative alignments generated by S4 were evaluated with 
statistical potential-based pG score and structure verification program Verify3D. pG 
score is the posterior probability that the model has a correct three-dimensional 
conformation, given its normalized z-score (obtained using the program Prosa II, (Sippl, 
1993)) and length. Verify3D assesses the compatibility of the segments of the sequence 
with their three-dimensional structures by plotting the average statistical preference 
scores in a window of 21 residues (Luthy et al., 1992). The best model among alternative 
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alignment had the pG score of 0.99. The minimum value of Verify3D profile window 
plot was 0.06. 
V5 PREX2 Purification for RAC-GEF assay: V5 PREX2 was purified from HEK293 
cells as previously described with small modifications (Fine et al., 2009). In short, 15 cm 
plates were transfected with V5 PREX2 and were harvested in 1.5mL of lysis buffer per 
plate (25 mM TRIS pH 7.4, 150 mM NaCl, 0.1% Triton X-100, 1 mM EDTA, 1 mM 
NaOV3, 1 mM NaF, 100 nM calyculin A, 1x eukaryotic protease inhibitor cocktail). 
Cells were vortexed and sonicated, then centrifuged for 1 hour at 40,000 x g. The 
supernatant was incubated with V5 agarose (10 μL per plate) for 16 hours rotating at 4°C. 
The beads were then washed on a poly-prep column (Bio-Rad) 4 times with lysis buffer 
and 4 times with buffer containing 1X PBS, 10% glycerol, 1 mM EGTA, and 1 mM 
DTT. Then 1.5 bed volumes of elution buffer (1X PBS, 10% glycerol, 1 mM EGTA, 1 
mM DTT, and 500 μg/mL V5 peptide (Sigma)) was added to the beads and the column 
was incubated at 37°C for 30 minutes. The column was then put into a 50 mL conical 
tube and centrifuged at 200 x g. This elution process was repeated a second time and 
elutions were combined. Protein samples were run on a gel with bovine serum albumin 
(BSA) standards and stained with Gel Code Blue (Thermo).  
Expression and purification of recombinant Gβ1His-γ2: Recombinant purified Gβγ 
dimers were produced as described elsewhere (Shymanets et al., 2013). Essentially, Fall 
armyworm ovary cells (Sf9, from Gibco BRL, Eggenstein, Germany) were cultured in 
suspension with TNM-FH medium (Sigma, Deisenhofen, Germany) supplemented with 
10 % (v/v) fetal calf serum (Gibco BRL), Lipid Medium Supplement (1:100; Sigma), 
penicillin (100 U/mL), and streptomycin (0.1 mg/mL). For protein expression, Sf9 cells 
120 
   
(1.5 x 106 cells/mL) were infected with viruses encoding Gβ1 and N-terminally 
hexahistidine-tagged Gγ2. After 60 hours of infection, cells were collected by 
centrifugation at 1,000 x g for 5 min and washed twice with PBS. Recombinantly 
expressed isoprenylated Gβ1His-γ2 complexes were isolated from the membrane fraction 
of Sf9 cells as detailed earlier (Shymanets et al., 2012; Shymanets et al., 2009). Purified 
proteins were quantified by SDS-PAGE followed by Coomassie blue staining with BSA 
standards and stored at -80 °C. 
In vitro RAC-GEF assay: Assay was performed as previously described with a few 
changes (Hill and Welch, 2006; Welch et al., 2002).  Purification of GST RAC1 proteins 
was performed as described above. After elution with glutathione, a 500 μL elution was 
combined in a 10,000 MWCO Amicon filter with 15 mL of buffer containing 40 mM 
HEPES pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, and 1 mM DTT. Solution 
was concentrated to 1mL and this was repeated 3 more times. The solution was removed 
from the filter, GDP was added to 1 mM, and the solution was rotated at 4°C for 1 hour. 
MgCl2 was then added to 15 mM to stop loading and the solution was added to a 10,000 
MWCO Amicon filter with 15mL of 40 mM HEPES pH 7.5, 150 mM NaCl, 1 mM 
EGTA, 1 mM DTT, 5 mM MgCl2, and 10 μM GDP. Solution was concentrated to 1 mL 
and this was repeated 3 more times. Final protein was snap frozen and stored at -80°C. 
For the in vitro GEF assay, PI(3,4,5)P3 diC16 was purchased from Echelon Biosciences 
and was incorporated into liposomes. Liposomes were prepared with 
phosphatidylcholine, phosphatidylserine, and phosphatidylinositol at 1 mM, which is a 
5X to the final assay concentration of 200 μM. In short, lipids were dried under argon 
gas, resuspended in lipid buffer (20 mM HEPES pH 7.5, 100 mM NaCl, 2 mM EGTA) 
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with or without PI(3,4,5)P3 diC16 (Echelon), and then sonicated. Then, 2 μL of lipids 
were added to 1 μL of 1 μM GST RAC1 (diluted in lipid buffer) and 1 μL of 10x assay 
buffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 100 mM NaCl, 1 mM EGTA, 100 
mg/mL BSA, 10 mM DTT). The solution was then vortexed and left on ice for 10 
minutes. Next, 4 μL purified V5 PREX2 from HEK293 cells was added, followed by 2 
μL of the 5X GTPγS master mix. The 5X GTPγS master mix consisted of 25 μM cold 
GTPγS and 0.5 μCi/μL [35S]GTPγS diluted in lipid buffer. The final concentrations of 
GST RAC1 and V5 PREX2 were 100 nM and 1 nM, respectively. In the final reaction, 
purified PREX2 and GST RAC1 were incubated in a reaction volume of 10 μL with 
PI(3,4,5)P3 or Gβγ, 5 μM cold GTPγS, and 1 μCi [35S]GTPγS (Perkin Elmer) for 10 
minutes at 30°C. Then GST RAC1 was pulled down by adding 400 μL of IP buffer (1X 
PBS, 1 mM EGTA, 10 mM MgCl2, 1% Triton, 0.1 mM GTP) and glutathione sepharose 
beads (GE Healthcare Life Sciences), and rotating for 1 hour at 4°C. The beads were then 
washed 4 times in IP buffer and resuspended in 400 μL of scintillation fluid. This was 
then added to a scintillation vial containing 5 mL of scintillation fluid, and the 
[35S]GTPγS-loading of GST RAC1 was detected by scintillation β counting. 
Invasion assay: Matrigel (Trevigen) was diluted in water to a final concentration of 0.15 
μg/μL in ice cold water and 40 μL of this dilution was put into the upper chamber of each 
Transwell (BD Biosciences) The Matrigel was dried at room temperature and 75 μL of 
empty media (no FBS) was added to the upper chamber. Then 600 μL of media with or 
without FBS was added to the lower chamber 30 minutes prior to starting the experiment. 
Empty vector or V5 PREX2 (WT or mutant) expressing BT549 cells were trypsinized 
and then allowed to recover in media with FBS. The cells were then washed twice in 
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empty media, counted, and either 50,000 cells (if using no chemoattractant), or 20,000 
cells (when using FBS as a chemoattractant) were plated into the upper chamber of the 
Transwell. Cells were allowed to invade for 22 hours (no chemoattractant) or 3 hours 
(FBS as a chemoatractant) at 37°C. Three independent Transwell inserts were used per 
experiment. Cells were removed from the top of the insert, and invading cells were fixed 
in methanol for 15 minutes and then stained with 0.2% crystal violet in 2% ethanol for 15 
minutes. Inserts were dried at room temperature, and pictures of at least 4 independent 
fields were taken per insert and invading cells were counted in each field. The average 
number of cells per field was calculated and data is presented as the fold-change increase 
over the average for the empty vector transfected cells. 
GST and PI(3,4,5)P3 bead pull downs -  For pull downs of V5 PREX2, HEK293 cells 
were transfected and then harvested in lysis buffer (20 mM HEPES pH 7.4, 0.25% NP-
40, 150 mM NaCl, 1 mM EDTA, 1 mM NaOV3, 1 mM NaF, 100 nM calyculin A, 1x 
eukaryotic protease inhibitor cocktail). Lysate was then vortexed, sonicated, and 
centrifuged at 4°C for 30 minutes. For pull downs with GST fused proteins, lysates were 
pre-cleared with GST loaded glutathione sepharose beads for 1 hour rotating at 4°C. 
Supernatants were then incubated with 5 μg of GST PTEN, GST PP1α, or GST RAC1 
loaded onto glutathione sepharose beads for 4 hours rotating at 4°C. For PI(3,4,5)P3 pull 
downs, 10 μL of PI(3,4,5)P3 bead slurry (Echelon) was incubated with lysates for 4 hours 
rotating at 4°C. Beads were washed 5 times in lysis buffer, and resuspended in 50 μL of 
2X Laemmli sample buffer. For PI(3,4,5)P3 pull downs of endogenous PREX2, the same 
protocol was followed except that the lysates from 15 cm plates of HEK293 cells were 
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divided into two samples, one for the PI(3,4,5)P3 pull down and another for the 
immunoprecipitation of PREX2 with 5 μL of PREX2 antibody. 
In vitro GST PP1α and PP2A dephosphorylation assay -  HEK293 cells were 
transfected with V5 PREX2, and cells were lysed in buffer containing 20 mM HEPES pH 
7.4, 0.25% NP-40, 150 mM NaCl, 1 mM EDTA, 1 mM NaOV3, 1 mM NaF, 100 nM 
calyculin A, and 1x eukaryotic protease inhibitor cocktail. The lysate was then vortexed, 
sonicated, and centrifuged at 4°C for 30 minutes. The supernatant was then incubated 
with V5 agarose beads for 4 hours rotating at 4°C. Next, the beads were washed 4 times 
in lysis buffer and once with either PP1α reaction buffer (50 mM TRIS pH 7.5, 150 mM 
NaCl, 0.1 mM EDTA, 1 mM MnCl2, 5 mM DTT) for PP1α assays, or protein 
phosphatase dilution buffer (Cat #: 20-169) from Millipore for PP2A assays. For PP1α 
dephosphorylation assays, 99 μL of PP1α reaction buffer was added to each tube 
followed by either 1 μL of GST elution buffer (25 mM TRIS pH 8.0, 100 mM NaCl, 50 
mM glutathione) for the mock treatment, or 1 μL of GST PP1α (at a concentration of 1 
μg/μL). For PP2A dephosphorylation assays, 45 μL of protein phosphatase dilution 
buffer was added to the V5 PREX2 beads, and then either 5 μL of protein phosphatase 
buffer or 0.5 units (5 μL) of purified PP2A (Millipore, Cat #:14-111) was added to each 
reaction. Reactions were incubated for 60 minutes at 30°C and stopped by removing the 
supernatant and resuspending the beads in 2X Laemmli sample buffer. 
Gβγ-PREX2 co-immunoprecipitation -  HEK293 cells were transfected with V5 PREX2 
alone, or V5 PREX2 and FLAG/HA Gβγ together. Cells co-expressing PREX2 and Gβγ 
were either untreated, or treated with 100 nM calyculin A for 30 minutes. Cells were 
lysed in buffer containing 25 mM TRIS pH 7.5, 0.2% Triton X-100, 200 mM KCl, 10% 
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glycerol, 1 mM EDTA, 1 mM EGTA, 1 mM NaOV3, 1 mM NaF, 100 nM calyculin A, 
and 1x eukaryotic protease inhibitor cocktail. Lysates were rotated at 4°C for 15 minutes, 
vortexed, and then spun down at 4°C for 30 minutes. Protein concentrations of lysates 
were measured using the Biorad DC protein assay and protein concentrations were 
equalized for all samples. Samples were then pre-cleared with Protein A/G Plus agarose 
beads rotating at 4°C for 1 hour. Finally, samples were incubated with 10 μL of M2-
FLAG agarose affinity gel for 4 hours rotating at 4°C. Beads were then washed 5 times in 
lysis buffer, and were resuspended in 2X Laemmli sample buffer. 
Cell fractionation - Either untransfected (for endogenous PREX2 analysis) or V5 PREX2 
transfected HEK293 cells were harvested in lysis buffer without detergents (50 mM TRIS 
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM NaOV3, 1 mM NaF, 100 nM calyculin A, 
1x eukaryotic protease inhibitor cocktail), and lysates were passed through a 25G needle 
10 times. The nuclear fraction was removed by centrifuging the lysate at 720 x g for 5 
minutes. The supernatant was centrifuged again at 17,000 x g for 20 minutes, followed by 
another spin at 17,000 x g for 10 minutes. The membrane fraction was separated by 
ultracenrifugation at 100,000 x g for 60 minutes. The supernatant (cytosolic fraction) was 
saved and the pellet (membrane fraction) was resuspended in 400 μL of lysis buffer 
without detergents and re-centrifuged at 100,000 x g for 45 minutes. For V5 PREX2, the 
pellet was resuspended in 100 μL of lysis buffer including 1% NP-40 and 0.25% sodium 
deoxycholate. For the endogenous fractionation, the membrane pellet was resuspended in 
400 μL of lysis buffer plus detergents, and GST PTEN beads (5 μg GST PTEN per 
sample) were incubated with both the cytosolic and membrane fraction for 4 hours 
rotating at 4°C to concentrate the endogenous PREX2 to be visualized by Western blot.  
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In vitro PAK kinase assay - V5 PREX2 expressing HEK293 cells were starved and then 
treated with 500 nM GDC0941 for 30 minutes. One 15 cm plate was transfected for every 
two kinase reactions in a given experiment. Each plate was harvested in 1.5 mL of high 
salt lysis buffer containing 25 mM TRIS pH 7.5, 0.1% Triton X-100, 1 M NaCl, and 1x 
eukaryotic protease inhibitor cocktail, and the lysates were then vortexed, sonicated, and 
centrifuged for 30 minutes at 4°C. Lysates were combined and then incubated with V5 
agarose beads for 4 hours rotating at 4°C. Beads were washed 3 times in lysis buffer 
followed by 3 washes with kinase buffer (25 mM MOPS, pH 7.2, 12.5 mM beta-
glycerophosphate, 25 mM MgCl2, 5 mM EGTA, 2 mM EDTA, 0.25 mM DTT), and then 
were divided equally into the appropriate number of tubes. Purified active PAK1 or 
PAK4 (SignalChem) was diluted in kinase dilution buffer (kinase buffer diluted 1:4 with 
50 ng/μl BSA). For the kinase reaction, 20 μL of volume, consisting of 10 μL PAK1 
(containing 0.4 μg of protein) or PAK4 (containing 0.2 μg of protein), 4 μL water, 1 μL 
PF-3758309 (MedKoo), 50 μM cold ATP, and 10 μCi [γ-32P]-ATP (both forms of ATP 
were diluted in kinase buffer), was incubated with the V5 PREX2 beads at 37°C for 30 
minutes. The PAK1 or PAK4, water, and PF-3758309 were incubated on ice for 10 
minutes before being added to the V5 PREX2 beads, and the cold and radioactive ATP 
was added to the reaction right before the incubation at 37°C. After the reaction, beads 
were then washed 2X in kinase buffer and resuspended in 2X Laemmli sample buffer. 
Incorporation of [γ-32P]-ATP was detected by gel electrophoresis.  
In vitro translation pull down assay using GST proteins: The TnT T7 Quick Coupled 
Transcription/Translation System from Promega was used to translate proteins in vitro. 
For the in vitro translation reactions, 20 μL of the TNT T7 master mix was combined 
126 
   
with 0.5μL of the supplied methionine stock, 1μg of DNA, and the appropriate amount of 
water to give a total reaction volume of 25 μL. The reactions were then incubated for 90 
minutes at 30°C. Each reaction was divided into two pull downs, one with GST beads and 
the other with either GST PTEN or GST RAC1 beads. Meanwhile, 10 μg of either GST, 
GST PTEN, or GST RAC1 sepharose beads (for each translation reaction, one tube of 
GST beads and one tube either GST PTEN or GST RAC1 beads were required) were 
blocked for 1 hour at 4°C in 500 μL of buffer containing 25 mM TRIS pH 7.5, 0.2% 
Triton X-100, 200 mM KCl, 10% glycerol, 1 mM EDTA, and 1 mg/ml BSA. After the in 
vitro translation reaction, 18 μL of the reaction was added to 1mL of the GST bead 
blocking buffer used above. 20 μg of GST beads were added to this solution to remove 
anything in the reaction that binds to GST. This mixture was rotated for 1 hour at 4°C. 
The buffer was removed from the beads being blocked, and 500 μL of the pre-cleared 
lysate was added to GST beads, while the other 500 μL was added to the GST PTEN or 
GST RAC1 beads. These pull downs were the left rotating overnight at 4°C. Beads were 
then washed 5 times in the same buffer used for the pull downs, excluding the BSA, and 
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